US20060194714A1 - Novel depsipeptides and process for preparing same - Google Patents

Novel depsipeptides and process for preparing same Download PDF

Info

Publication number
US20060194714A1
US20060194714A1 US11/414,762 US41476206A US2006194714A1 US 20060194714 A1 US20060194714 A1 US 20060194714A1 US 41476206 A US41476206 A US 41476206A US 2006194714 A1 US2006194714 A1 US 2006194714A1
Authority
US
United States
Prior art keywords
compound
amino
formula
methyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/414,762
Inventor
John Finn
Michael Morytko
Ian Parr
Michael Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Priority to US11/414,762 priority Critical patent/US20060194714A1/en
Publication of US20060194714A1 publication Critical patent/US20060194714A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel depsipeptides compounds.
  • the invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial agents.
  • the invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.
  • a class of compounds that have shown potential as useful antibiotic agents is the cyclic depsipeptides.
  • a notable member of the cyclic depsipeptides is the A-21978C lipopeptides described in, for example, U.S. Pat. RE 32,333; RE 32,455; RE 32,311; RE 32,310; U.S. Pat. Nos. 4,482,487; 4,537,717; and 5,912,226 and International Patent Applications WO01/44272; WO01/44274; and WO01/44271. Additionally, the A54145 class of compounds described in U.S. Pat. Nos. 4,994,270; 5,039,789; and 5,028,590 have also been shown to possess antibiotic activity.
  • Daptomycin also known as LY 146032, is comprised of an n-decanoyl side chain linked to the N-terminal tryptophan of a three-amino acid chain linked to a cyclic 10-amino acid peptide. Daptomycin has potent bactericidal activity in vitro and in vivo against clinically relevant gram-positive bacteria that cause serious and life-threatening diseases.
  • VRE vancomycin-resistant enterococci
  • MRSA methicillin-resistant Staphylococcus aureus
  • GISA glycopeptide intermediate susceptible Staphylococcus aureus
  • VRSA vancomycin-resistant Staphylococcus aureus
  • CNS vancomycin-resistant Staphylococcus aureus
  • PRSP penicillin-resistant Streptococcus pneumoniae
  • novel antibacterial agents would be expected to be useful to treat not only “natural” pathogens, but also intermediate drug resistant and drug resistant pathogens because the pathogen has never been exposed to the novel antibacterial agent.
  • New antibacterial agents may exhibit differential effectiveness against different types of pathogens.
  • the present invention provides novel compounds that have antibacterial activity against a broad spectrum of bacteria, including drug-resistant bacteria, and processes for making these compounds.
  • the present invention provides, in one aspect, compounds of Formula I: and salts thereof; wherein:
  • R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • each R 1 and R 6 is independently hydrido or methyl
  • R 2 is methyl or —CH 2 CH 2 CH 2 R 8 ;
  • R 3 is methyl or —CH 2 CH 2 CH 2 CH 2 R 9 ;
  • R 4 is hydrido or methoxy
  • R 5 is hydroxy or carboxyamino
  • each of R 7 , R 8 and R 9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
  • the present invention also provides pharmaceutical compositions including compounds of Formula I and methods of use thereof.
  • the present invention provides a process for preparing the compounds of Formula I.
  • the invention provides compounds useful as intermediates for the preparation of the compounds of Fomula I.
  • activating group denotes a group that when adjacent to a carbonyl group activates the carbonyl group to attack by a nucleophilic amine, resulting in the loss of the activating group and the formation of an amide bond.
  • activating groups are aryloxy, acyloxy, imidazolyl
  • Preferred activating groups are aryloxy groups.
  • the most preferred activating group is pentafluorophenoxy.
  • acyl denotes a carbonyl radical attached to an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycyl, aryl or heteroaryl group, examples including, without limitation, such radicals as acetyl and benzoyl.
  • Subsets of the term acyl are (1) “unsubstituted alkanoyl” which is defined as carbonyl radical attached to an unsubstituted alkyl group and (2) “unsubstituted alkenoyl” which is defined as carbonyl radical attached to an unsubsituted alkenyl group.
  • acylamino is defined as a nitrogen radical adjacent to an acyl group.
  • acyloxy denotes an oxygen radical adjacent to an acyl group.
  • alkenyl is defined as linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon double bond.
  • One or more hydrogen atoms can also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido,
  • the double bond portion(s) of the unsaturated hydrocarbon chain may be either in the cis or trans configuration.
  • alkenyl groups include, without limitation, ethylenyl or phenyl ethylenyl.
  • a subset of term alkenyl is “unsubstituted alkenyl” which is defined as an alkenyl group that bears no substituent groups.
  • alkoxy denotes oxygen radical substituted with an alkyl, cycloalkyl or heterocyclyl group. Examples include, without limitation, methoxy, tert-butoxy, benzyloxy and cyclohexyloxy.
  • alkyl is defined as a linear or branched, saturated radical having one to about twenty carbon atoms unless otherwise specified.
  • the term “lower alkyl” is defined as an alkyl group containing 1-4 carbon atoms.
  • One or more hydrogen atoms can also be replaced by a substitutent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamin
  • alkyl groups include, without limitation, methyl, butyl, tert-butyl, isopropyl, trifluoromethyl, nonyl, undecyl, octyl, dodecyl, methoxymethyl, 2-(2′-aminophenacyl), 3-indolylmethyl, benzyl, and carboxymethyl.
  • alkyl is defined as an alkyl group that bears no substituent groups
  • substituted alkyl which denotes an alkyl radical in which one or more hydrogen atoms is replaced by a substitutent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino,
  • alkylidenyl is defined as a carbon radical of the formula wherein R x and R x1 are independently selected from hydrido or C 7 -C 17 unsubstituted alkyl, wherein the total number of carbons from R x and R x1 does not exceed 17.
  • alkynyl denotes linear or branched radicals having from two to about ten carbon atoms, and containing at least one carbon-carbon triple bond.
  • One or more hydrogen atoms can also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido.
  • amino is defined as an NH 2 radical.
  • amino acid resisue denotes a compound of the formula wherein R aa is an amino acid side chain.
  • amino acid side chain denotes any side chain (R group) from a naturally-occurring or synthetic amino acid.
  • R group side chain from a naturally-occurring or synthetic amino acid.
  • 3-indolylmethyl could also be called a tryptophan side chain.
  • amino protecting group refers to any chemical compound that may be used to prevent an amino group on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule. Numerous amino protecting groups are known to those skilled in the art and examples can be found in “Protective Groups in Organic Synthesis” by Theodora W. Greene, John Wiley and Sons, New York, 1981.
  • amino protecting groups examples include phthalimido, trichloroacetyl, STA-base, benzyloxycarbonyl, t-butoxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, adamantyloxycarbonyl, chlorobenzyloxycarbonyl, nitrobenzyloxycarbonyl or the like.
  • Preferred amino protecting groups are “carbamate amino protecting groups” which are defined as an amino protecting group that when bound to an amino group forms a carbamate.
  • Preferred amino carbamate protecting groups are allyloxycarbonyl (alloc), carbobenzyloxy (CBZ), and tert-butoxycarbonyl protecting groups.
  • aryl or “aryl ring” is defined as an aromatic radical in a single or fused carbocyclic ring system, having from five to fourteen ring members. In a preferred embodiment, the ring system has from six to ten ring members.
  • One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio,
  • aryloxy denotes oxy-containing radicals substituted with an aryl or heteroaryl group. Examples include, without limitation, phenoxy.
  • carbamoyl denotes a nitrogen radical of the formula wherein R x2 is selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl and R x3 is selected from alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl
  • carboalkoxy is defined as a carbonyl radical adjacent to an alkoxy or aryloxy group.
  • carboxyamido is defined as a carbonyl radical adjacent to a monosubstituted amino or disubstituted amino group.
  • ⁇ -carboxy amino acid side chain is defined as a carbon radical of the formula
  • R x4 is defined as an amino acid side chain.
  • cycloalkyl or “cycloalkyl ring” denotes a saturated or partially unsaturated carbocyclic ring in a single or fused carbocyclic ring system having from three to twelve ring members.
  • a cycloalkyl is a ring system having three to seven ring members.
  • One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido.
  • a cycloalkyl group include, without limitation, cyclopropyl, cyclobutyl, cyclohexyl, and cyclohept
  • disubstituted amino is defined as a nitrogen radical containing two substituent groups independently selected from, alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • Preferred disubstituted amino radicals are “lower disubstituted amino” radicals, whereby the substituent groups are lower alkyl.
  • Also preferred disubstituted amino radicals are amino radicals wherein one substituent is a lower alkyl group and the other substituent is an ⁇ -carboxy amino acid side chain.
  • the group “Fmoc” is a 9-fluorenylmethoxycarbonyl group.
  • R x5 , R x7 and R x8 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and R x6 is selected from alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • halo denotes a bromo, chloro, fluoro or iodo radical.
  • Heteroaryl or “heteroaryl ring” is defined as an aromatic radical which contain one to four hetero atoms or hetero groups selected from O, N, S, or SO in a single or fused heterocyclic ring system, having from five to fifteen ring members.
  • the heteroaryl ring system has from six to ten ring members.
  • One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido.
  • a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino
  • heteroaryl groups include, without limitation, pyridinyl, thiazolyl, thiadiazoyl, isoquinolinyl, pyrazolyl, oxazolyl, oxadiazoyl, triazolyl, and pyrrolyl groups.
  • heterocyclyl denotes a saturated or partially unsaturated ring containing one to four hetero atoms or hetero groups selected from O, N, NH, N (lower alkyl), S, SO or SO 2 , in a single or fused heterocyclic ring system having from three to twelve ring members.
  • a heterocyclyl is a ring system having three to seven ring members.
  • One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido.
  • a heterocyclyl group include, without limitation, morpholinyl, piperidinyl, and pyrrolidinyl.
  • hydro is defined as a single hydrogen atom (H).
  • aminoamino denotes a nitrogen radical of the formula:
  • each of R x9 and R x11 is independently selected from a hydrido, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group; and R x10 is selected from an alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group.
  • modifying agent is defined as (a) a nucleophilic acceptor or (b) an aldehyde or ketone that reacts with an amine-under reductive conditions to form an alkylated amine.
  • monosubstituted amino denotes a nitrogen radical containing a hydrido group and a substituent group selected from alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • Preferred monosubstituted amino radicals are “lower monosubstituted amino” radicals, whereby the substituent group is a lower alkyl group. More preferred monosubstituted amino radicals are amino radicals containing an ⁇ -carboxy amino acid side chain.
  • nucleophilic acceptor is defined as a compound that is susceptible to nucleophilic attack by a primary or secondary amine.
  • nucleophilic acceptors include, without limitation, isocyanates, isothiocyanates, activated esters, acid chlorides, sulfonyl chlorides, activated sulfonamides, activated heterocycles, activated heteroaryls, chloroformates, cyanoformates, thioesters, phosphoryl chlorides, phosphoramidates, imidates, and lactones.
  • phosphonamino is defined as a nitrogen radical of the Formula: wherein R x12 is selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl; wherein each of R x13 and R x14 is independently selected from alkyl, alkoxy, aryl, aryloxy, cycloalkyl, heteroaryl and heterocyclyl.
  • sulfinyl denotes a tetravalent sulfur radical substituted with an oxo substituent and a second substituent selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl group.
  • sulfonamino is defined as an amino radical of the formula:
  • R x15 is selected from a hydrido, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group; and R x16 is selected from alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group.
  • sulfonyl denotes a hexavalent sulfur radical substituted with two oxo substituents and a third substituent selected from alkyl, cycloalkyl, heterocyclyl aryl, or heteroaryl.
  • thio is defined as a radical containing a substituent group independently selected from hydrido, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, attached to a divalent sulfur atom, such as, methylthio and phenylthio.
  • thioacylamino denotes an amino radical of the formula
  • R x17 is selected from a hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and wherein R x18 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • thioureido is defined as a sulfur radical of the formula
  • each of R x19 and R x20 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and R x21 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • the group trityl is a triphenylmethyl group.
  • ureido is defined as a nitrogen radical of the formula
  • each of R x21 and R x22 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and R x23 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • the salts of the compounds of the invention include acid addition salts and base addition salts.
  • the salt is a pharmaceutically acceptable salt of the compound of Formula I.
  • pharmaceutically acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared from an inorganic acid or an organic acid. Examples of such inorganic acids include, without limitation, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include, without limitation, formic, acetic, propionic, succinic, glycolic, gluconic, maleic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, ⁇ -hydroxybutyric, malonic, galactic, and galacturonic acid.
  • Suitable pharmaceutically-acceptable base addition salts of compounds of the invention include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine and procaine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by treating, for example, the compound of the invention with the appropriate acid or base.
  • the compounds of the invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof.
  • the compounds of the invention can be utilized in the present invention as a single isomer or as a mixture of stereochemical isomeric forms.
  • Diastereoisomers, i.e., nonsuperimposable stereochemical isomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation.
  • the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base.
  • Examples of appropriate acids include, without limitation, tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • the mixture of diastereomers can be separated by crystallization followed by liberation of the optically active bases from the optically active salts.
  • An alternative process for separation of optical isomers includes the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
  • Still another method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate.
  • the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to obtain the enantiomerically pure compound.
  • the optically active compounds of the invention can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • the invention also embraces isolated compounds.
  • An isolated compound refers to a compound which represents at least 10%, preferably at least 20%, more preferably at least 50% and most preferably at least 80% of the compound present in the mixture.
  • the compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound exhibits a detectable (i.e. statistically significant) antimicrobial activity when tested in conventional biological assays such as those described herein.
  • the invention provides compounds of Formula I and salts thereof; wherein:
  • R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • each R 1 and R 6 is independently hydrido or methyl
  • R 2 is methyl or —CH 2 CH 2 CH 2 R 8 ;
  • R 3 is methyl or —CH 2 CH 2 CH 2 CH 2 R 9 ;
  • R 4 is hydrido or methoxy
  • R 5 is hydroxy or carboxyamino
  • each of R 7 , R 8 and R 9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
  • R 7 is
  • R is 2-(2′-aminophenacyl); each of R 1 and R 4 is hydrido; R 2 is —CH 2 CH 2 CH 2 R 8 ; each of R 3 and R 6 is methyl; and R 5 is hydroxyl.
  • This embodiment provides a compound of Formula II.
  • R is isopropyl or 2-butyl; each of R 1 and R 2 is methyl; R 3 is —CH 2 CH 2 CH 2 CH 2 R 9 ; R 4 is methoxy, and R 5 carboxyamino.
  • R 14 is hydrido or methyl.
  • Table I provides exemplary compounds of Formula II. TABLE I Compounds of Formula II R 7 R 8 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2
  • R 7 ** is an amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino and each of R aa4 , R aa5 , and R aa6 is independently an amino acid side chain.
  • Table II provides exemplary compounds of Formula III. TABLE II Compounds of Formula III R 7 R 9 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2 NH 2
  • R 7 ** is an amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino and each of R aa4 , R aa5 , and R aa6 is independently an amino acid side chain.
  • the present invention also provides compounds of the Formula IV that are particularly useful as intermediates for the preparation of the compounds of Formula I. and salts thereof; wherein:
  • R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • each R 1 and R 6 is independently hydrido or methyl
  • R 4 is hydrido or methoxy
  • R 5 is hydroxy or carboxyamino
  • R 16 is methyl or —CH 2 CH 2 CH 2 R 21 ;
  • R 17 is methyl or —CH 2 CH 2 CH 2 CH 2 R 22 ;
  • each of R 21 and R 22 is —NHR 23 , wherein R 23 is an amino protecting group.
  • R 23 is a carbamate amino protecting group selected from allyloxycarbonyl, carbobenzyloxycarbonyl and tert-butoxycarbonyl. In the most preferred embodiment R 23 is allyloxycarbonyl.
  • the present invention provides intermediates of the Formulas V, VI, VII, VIII, IX and X that are particularly useful as intermediates for the preparation of the compounds of Formula I. wherein R 6 and R 14 are as previously defined. wherein R 6 and R 14 are as previously defined. wherein R 6 and R 14 are as previously defined. Pharmaceutical Compositions and Methods of Use Thereof
  • the instant invention provides pharmaceutical compositions or formulations comprising compounds of Formula I, or salts thereof.
  • Compounds of the present invention can be formulated for oral, intravenous, intramuscular, subcutaneous or parenteral administration for the therapeutic or prophylactic treatment of diseases, particularly bacterial infections.
  • compounds of the present invention can be mixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers and the like.
  • the compositions comprising a compound of this invention will contain from about 0.1 to about 99% by weight of the active compound, and more generally from about 10 to about 30%.
  • compositions of the present invention preferably compounds of Formula I, can be delivered using controlled (e.g., capsules) or sustained release delivery systems (e.g., bioerodable matrices).
  • compositions of the present invention comprise one or more compounds of the invention, preferably compounds of Formula I, in association with one or more nontoxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants and/or excipients, collectively referred to herein as “carrier” materials, and if desired other active ingredients.
  • carrier materials
  • the compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid.
  • the compositions may contain croscarmellose sodium, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
  • Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.
  • Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
  • Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. It may also be desirable to add a coloring agent to make the dosage form more aesthetic in appearance or to help identify the product.
  • the pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a therapeutically-effective amount of the active ingredient. Examples of such dosage units are tablets and capsules.
  • the tablets and capsules which can contain, in addition to the active ingredient, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants, for example, magnesium stearate, polyethylene glycol, silica, or talc; disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents.
  • binding agents for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth
  • fillers for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose
  • lubricants for example, magnesium stearate, polyethylene glycol, silica, or talc
  • disintegrants
  • Oral liquid preparations generally are in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents.
  • additives for liquid preparations include acacia, almond oil, ethyl alcohol, fractionated coconut oil, gelatin, glucose syrup, glycerin, hydrogenated edible fats, lecithin, methyl cellulose, methyl or propyl para-hydroxybenzoate, propylene glycol, sorbitol, or sorbic acid.
  • IV intravenous
  • a compound of the present invention can be dissolved or suspended in any of the commonly used intravenous fluids and administered by infusion.
  • Intravenous fluids include, without limitation, physiological saline or Ringer's solution.
  • Intravenous administration may be accomplished by using, without limitation, syringe, minipump or intravenous line.
  • Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions or suspensions can be prepared from sterile powders or granules having one or more of the carriers mentioned for use in the formulations for oral administration.
  • the compounds can be dissolved in polyethylene glycol, propylene glycol, ethanol, corn oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • a sterile formulation of a compound of the present invention, or a suitable soluble salt form of the compound, for example the hydrochloride salt can be dissolved and administered in a pharmaceutical diluent such as Water-for-Injection (WFI), physiological saline or 5% glucose.
  • WFI Water-for-Injection
  • a suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g., an ester of a long chain fatty acid such as ethyl oleate.
  • a dose of an intravenous, intramuscular or parental formulation of a compound of the present invention may be adminstered as a bolus or by slow infusion.
  • a bolus is a dose that is administered in less than 30 minutes. In a preferred embodiment, a bolus is administered in less than 15 or less than 10 minutes. In a more preferred embodiment, a bolus is administered in less than 5 minutes. In an even more preferred embodiment, a bolus is administered in one minute or less.
  • An infusion is a dose that is administered at a rate of 30 minutes or greater. In a preferred embodiment, the infusion is one hour or greater. In another embodiment, the infusion is substantially constant.
  • the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of creams, ointments, liquid sprays or inhalants, lozenges, or throat paints.
  • suitable forms can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient.
  • DMSO dimethylsulfoxide
  • the compounds of the present invention preferably compounds of Formula I, can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.
  • the compounds of the present invention preferably compounds of Formula I
  • the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.
  • the unit dosage form of the compound can be a solution of the compound or preferably a salt thereof in a suitable diluent in sterile, hermetically sealed ampoules or sterile syringes.
  • the concentration of the compound in the unit dosage may vary, e.g. from about 1 percent to about 50 percent, depending on the compound used and its solubility and the dose desired by the physician.
  • each dosage unit preferably contains from 1-500 mg of the active material.
  • the dosage employed preferably ranges from 5 mg to 10 g, per day, depending on the route and frequency of administration.
  • the invention provides a method for inhibiting the growth of microorganisms, preferably bacteria, comprising contacting said organisms with a compound of the present invention under conditions which permit contact of the compound with said organism and with said microorganism.
  • a compound of the present invention under conditions which permit contact of the compound with said organism and with said microorganism.
  • This method involves contacting a microbial cell with a therapeutically-effective amount of compound(s) of the invention, preferably compound(s) of Formula I, in vivo or in vitro.
  • the novel compositions disclosed herein are placed in a pharmaceutically acceptable carrier and are delivered to a recipient subject (preferably a human) in accordance with known methods of drug delivery.
  • a recipient subject preferably a human
  • the methods of the invention for delivering the compositions of the invention in vivo utilize art-recognized protocols for delivering the agent with the only substantial procedural modification being the substitution of the compounds of the present invention, preferably compounds of Formula I, for the drugs in the art-recognized protocols.
  • the methods for using the claimed composition for treating cells in culture utilize art-recognized protocols for treating cell cultures with antibacterial agent(s) with the only substantial procedural modification being the substitution of the compounds of the invention, preferably compounds of Formula I, for the agents used in the art-recognized protocols.
  • the invention provides a method for treating an infection, especially those caused by gram-positive bacteria, in a subject with a therapeutically-effective amount of a compound of the invention.
  • a therapeutically-effective amount means an amount of a compound of the present invention that prevents the onset, alleviates the symptoms, or stops the progression of a bacterial infection.
  • treating is defined as administering, to a subject, a therapeutically-effective amount of a compound of the invention both to prevent the occurrence of an infection and to control or eliminate an infection.
  • subject as described herein, is defined as a mammal, a plant or a cell culture. In a preferred embodiment, a subject is a human or other animal patient in need of antibacterial treatment.
  • the method comprises administering to the subject an effective dose of a compound of the present invention.
  • An effective dose is generally between about 0.1 and about 100 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof.
  • a preferred dose is from about 0.1 to about 50 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof.
  • a more preferred dose is from about 1 to 25 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof.
  • An effective dose for cell culture is usually between 0.1 and 1000 ⁇ g/mL, more preferably between 0.1 and 200 ⁇ g/mL.
  • compositions containing the compounds of the invention can be administered as a single daily dose or in multiple doses per day.
  • the treatment regime may require administration over extended periods of time, e.g., for several days or for from two to four weeks.
  • the amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the patient, the tolerance of the patient to the compound and the microorganism or microorganisms involved in the infection.
  • a method of administration to a patient of daptomycin, another member of the depsipeptide compound class is disclosed in U.S. Ser. No. 09/406,568, filed Sep. 24, 1999, which claims the benefit of U.S. Provisional Application No. 60/101,828, filed Sep. 25, 1998, and 60/125,750, filed Mar. 24, 1999, the contents of which are herein incorporated by reference.
  • a compound of the present invention may also be administered in the diet or feed of a patient or animal. If administered as part of a total dietary intake, the amount of compound employed can be less than 1% by weight of the diet and preferably no more than 0.5% by weight.
  • the diet for animals can be normal foodstuffs to which the compound can be added or it can be added to a premix.
  • the present invention also provides methods of administering a compound of Formula I or a pharmaceutical composition thereof to a subject in need thereof in an amount that is efficacious in reducing or eliminating the bacterial infection.
  • the compound may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally, vaginally, or by an implanted reservoir, external pump or catheter.
  • the compound may be prepared for opthalmic or aerosolized uses.
  • the compounds of the present invention can be administered as an aerosol for the treatment of pneumonia or other lung-based infections.
  • a preferred aerosol delivery vehicle is an anhydrous or dry powder inhaler.
  • Compounds of Formula I or a pharmaceutical composition thereof may also be directly injected or administered into an abscess, ventricle or joint.
  • Parenteral administration includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, cisternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion.
  • the compounds of the present invention are administered intravenously, subcutaneously or orally.
  • the compound may be administered in a nutrient medium.
  • the method of the instant invention may be used to treat a subject having a bacterial infection in which the infection is caused or exacerbated by any type of bacteria, particularly gram-positive bacteria.
  • a compound of the present invention or a pharmaceutical composition thereof is administered to a patient according to the methods of this invention.
  • the bacterial infection may be caused or exacerbated by gram-positive bacteria.
  • gram-positive bacteria include, but are not limited to, methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S.
  • Clostridium difficile C. clostridiiforme, C. innocuum, C. perfringens, C. ramosum, Haemophilus influenzae, Listeria monocytogenes, Corynebacterium jeikeium, Bifidobacterium spp., Eubacterium aerofaciens, E. lentum, Lactobacillus acidophilus, L. casei, L. plantarum, Lactococcus spp., Leuconostoc spp., Pediococcus, Peptostreptococcus anaerobius, P. asaccarolyticus, P. magnus, P. micros, P.
  • the antibacterial activity of compounds of Formula I against classically “resistant” strains is comparable to that against classically “susceptible” strains in in vitro experiments.
  • the minimum inhibitory concentration (MIC) value for compounds according to this invention against susceptible strains is typically the same or lower than that of vancomycin.
  • a compound of this invention or a pharmaceutical composition thereof is administered according to the methods of this invention to a patient who exhibits a bacterial infection that is resistant to other compounds, including vancomycin or daptomycin.
  • depsipeptide compounds such as those disclosed in the present invention, exhibit rapid, concentration-dependent bactericidal activity against gram-positive organisms.
  • a compound according to this invention or a pharmaceutical composition thereof is administered according to the methods of this invention to a patient in need of rapidly acting antibiotic therapy.
  • the method of the instant invention may be used for any bacterial infection of any organ or tissue in the body.
  • the bacterial infection is caused by gram-positive bacteria.
  • organs or tissue include, without limitation, skeletal muscle, skin, bloodstream, kidneys, heart, lung and bone.
  • the method of the invention may be used to treat, without limitation, skin and soft tissue infections, bacteremia and urinary tract infections.
  • the method of the invention may be used to treat community acquired respiratory infections, including, without limitation, otitis media, sinusitis, chronic bronchitis and pneumonia, including pneumonia caused by drug-resistant S. pneumoniae or H. influenzae .
  • the method of the invention also may be used to treat mixed infections that comprise different types of gram-positive bacteria, or which comprise both gram-positive and gram-negative bacteria. These types of infections include intra-abdominal infections and obstetrical/gynecological infections.
  • the method of the invention also may be used to treat an infection including, without limitation, endocarditis, nephritis, septic arthritis, intra-abdominal sepsis, bone and joint infections. and osteomyelitis.
  • any of the above-described diseases may be treated using compounds according to this invention or pharmaceutical compositions thereof.
  • the method of the present invention may also be practiced while concurrently administering one or more other antimicrobial agents, such as antibacterial agents (antibiotics) or antifungal agents.
  • the method may be practiced by administering more than one compound according to this invention.
  • the method may be practiced by administering a compound according to this invention with a lipopeptide compound, such as daptomycin or the lipopeptide compounds described, for example in International Patent Applications WO01/44272; WO01/44274; and WO01/44271.
  • Antibacterial agents and classes thereof that may be co-administered with a compound according to the invention include, without limitation, penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents including sulfonamides, trimethoprim and its combinations and pyrimethamine, synthetic antibacterials including nitrofurans, methenamine mandelate and methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide
  • Antifungal agents that may be co-administered with a compound according to the invention include, without limitation, Caspofingen, Voriconazole, Sertaconazole, IB-367, FK-463, LY-303366, Sch-56592, Sitafloxacin, DB-289 polyenes, such as Amphotericin, Nystatin, Primaricin; azoles, such as Fluconazole, Itraconazole, and Ketoconazole; allylamines, such as Naftifine and Terbinafine; and anti-metabolites such as Flucytosine.
  • Fostel et al. discloses antifingal compounds including Corynecandin, Mer-WF3010, Fusacandins, Artrichitin/LL 15G256, Sordarins, Cispentacin, Azoxybacillin, Aureobasidin and Khafrefungin.
  • a compound according to this invention may be administered according to this method until the bacterial infection is eradicated or reduced.
  • a compound of Formula I is administered for a period of time from 2 days to 6 months.
  • a compound of Formula I is administered for 7 to 56 days.
  • a compound of Formula I is administered for 7 to 28 days.
  • a compound of Formula I is administered for 7 to 14 days.
  • a compound of Formula I may be administered for a longer or shorter time period if it is so desired.
  • the semisynthetic process comprises providing a compound of the Formula XI (step (a)).
  • Compounds of Formula XI can be obtained by methods disclosed in U.S. Pat. RE 32,333; RE 32,455; RE 32,311; U.S. Pat. Nos. 4,482,487; 4,537,717; 4,800,157, 4,874,843; 4,885,243; 5,912,226; 4,994,270; 5,039,789; and 5,028,590; International Patent Application Serial Numbers WO01/44272, WO01/44274, WO01/44271, WO01/53330, and WO02/059,322 each of which is incorporated herein by reference.
  • the compound of Formula XI is one in which, each of R 1 and R 4 is hydrido; each of R 3 and R 6 is methyl; R 5 is hydroxyl; R 25 is 7-methylnonyl, 9-methyldecyl, 9-methylundecyl, nonyl, decyl or mixtures thereof and R 26 is —CH 2 CH 2 CH 2 NH 2 .
  • the compound of Formula XI is one in which R is isopropyl or 2-butyl; each of R 1 and R 2 is methyl; R 4 is methoxy, R 5 is carboxyamino; R 25 is 8-methylnonanoyl, n-decanoyl, or 8-methyldecanoyl; and R 27 is —CH 2 CH 2 CH 2 CH 2 NH 2 .
  • step (b) The free amine of the compound of Formula XI is treated with a protecting group to give a protected depsipeptide compound of Formula XII (step (b)), wherein: R, R 1 , R 4 , R 5 , R 6 , R 18 , R 19 , R 20 , and R 25 are as described previously; R 28 is methyl or —CH 2 CH 2 CH 2 NHP; R 29 is methyl or —CH 2 CH 2 CH 2 CH 2 NHP; wherein P is an amino protecting group or a salt thereof.
  • amino protecting groups examples include carbamate amino protecting groups. More preferred amino groups are allyloxycarbonyl (alloc), carbobenzyloxy (CBZ), and tert-butoxycarbonyl protecting groups. The most preferred carbamate amino protecting group is allylyoxycarbonyl.
  • Methods of protecting the amine of daptomycin, A54145 and related lipopeptides can be found in U.S. Pat. RE 32,310; RE 32,311; U.S. Pat. Nos. 4,482,487; 4,524,135, 4,537,717; 5,039,789; and 5,028,590; International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271.
  • deacylating agents suitable for the invention are enzymatic deacylating agents.
  • An enzyme which is useful for deacylation of a compound of Formula XII is produced by certain microorganism of the family Actinoplanaceae.
  • Actinoplanes philippinensis Actinoplanes armeniacus, Actinoplanes utahensis, Actinoplanes missouriensis, Spirillospora albida, Streptosporiangium roseum, Streptosporangium vulgare, Streptosporangium roseum var hollandernsi, Streptosporangium album, Streptosporangium viridialbum, Amorphosporangium auranticolor, Ampullariella regularis, Ampullariella campanulata, Ampullariella lobata, Ampullariella digitata, Pilimelia terevasa, Pimelia anulata, Planomonospora parontospora, Planomonospora venezuelensis, Planobispora longispora, Planobispora rosea, Dactylosporangium aurantiacum , and Dactylo
  • Preferred sources of the deacylation enzyme are Actinoplanes utahensi : NRRL 12052 ; Actinoplanes missouriensis NRRL 12053; Actinoplanes sp.: NRRL8122, Actinoplanes sp.: NRRL 12065 , Streptosporsngium roseum var hollandernsis : NRRL 12064 , Actinoplanes utahenis ATCC 14539 and Actinoplanes missouriensis ATCC 14538.
  • the more preferred source of deacylation enzyme is the species Actinoplanes utahensi .
  • deacylation enzyme is one produced from recombinant Streptomyces lividans , which expresses the Actinoplanes utahensis deacylation enzyme as described in J. Ind. Microbiol. Biotechnol. 2000, 24(3) 173-180. This enzyme is also known as echinocandin B deacylase or ECB deacylase.
  • Suitable methods for enzymatic deacylation of compounds of Formula XII can be found in U.S. Pat. Nos. 4,524,135; 4,537,717; 4,482,487; RE 32,310, RE 32,311 U.S. Pat. Nos. 5,039,789 and 5,028590; International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271; each herein incorporated by reference.
  • Step (d) Removal of the tryptophan amino acid residue from the terminal amino compound of Formula XIII leads to the formation of the compound of Formula XIV (step (d)).
  • Methods for removal of the tryptophan amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the tryptophan amino acid residue is under Edman degradation conditions.
  • the Edman degradation is a well-established reaction known to those skilled in the art (see, for example, P. Edman, 1950 , Acta Chem. Scan. 4: 283-93 and P. Edman, 1956 , Acta Chem Scan 10: 761-768).
  • the terminal NH 2 group of a peptide reacts with an isothiocycanate to form a thiourea derivative of the peptide.
  • the thiourea peptide undergoes a cyclization reaction, giving a thiohydantoin and a shorter peptide (see Scheme II).
  • R 30 , R 31 , and R 32 are each an amino acid side chain; and R 33 is an aryl or alkyl group.
  • the Edman degradation can be carried out under a variety of conditions.
  • the isothiocyanate reacts with the amine under neutral to mildly basic (pH ⁇ 9.5) conditions in solvents such as tetrahydrofuran, N,N′-dimethylformamide, dichloromethane, dioxane or ethanol.
  • solvents such as tetrahydrofuran, N,N′-dimethylformamide, dichloromethane, dioxane or ethanol.
  • isothiocyanates can be used (see K. K. Han et al. Biochemie 1977, 59: 557-576.
  • the thiourea peptide (the compound of Formula XVIII) formed upon reaction of the thioisocyanate with a compound of Formula XIII is treated under acidic conditions to provide a compound of Formula XIV.
  • a compound of Formula XVIII is treated with trifluoroacetic acid to give the compound of Formula XIV (Scheme III).
  • R 33 is phenyl, n-decyl, nonyl or octyl. In a more preferred embodiment, R 33 is n-decyl.
  • Step (e) Removal of the terminal amino acid residue from the compound of Formula XIV leads to the formation of the desdipeptide compound of Formula XV (step (e)).
  • Methods for removal of the terminal amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • the thiourea peptide (the compound of Formula XIX) formed upon reaction of the thioisocyanate with a compound of Formula XIV, is treated under acidic conditions to provide desdipeptide compound of Formula XV.
  • a compound of Formula XIX is treated with trifluoroacetic acid to give the compound of Formula XV (Scheme IV).
  • R 34 is alkyl or aryl.
  • Step (f) Removal of the terminal amino acid residue from the compound of Formula XV leads to the formation of the depsipeptide core compound of Formula XVI (step (f)).
  • Methods for removal of the terminal amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • the thiourea peptide (the compound of Formula XX) formed upon reaction of the thioisocyanate with a compound of Formula XV, is treated under acidic conditions to provide the depsipeptide core compound of Formula XVI.
  • a compound of Formula XX is treated with trifluoroacetic acid to give the compound of Formula XVI (Scheme IV A).
  • R 35 is alkyl or aryl.
  • Treatment of the depsipeptide core compound of Formula XVI with a modifying agent results in the formation of protected Formula I compound (the compound of Formula XVII, step (f)).
  • the reaction of an amine with modifying agents, as defined herein, is well known to those skilled in the art.
  • treatment of a compound of Formula XVI with an isocyanate gives compounds of Formula XVII in which R 7 is ureido.
  • treatment of a compound of Formula XVI with an activated ester, lactone or acid chloride yields compounds of Formula XVII in which R 7 is acylamino.
  • Treatment of a compound of Formula XVI with a sulfonyl chloride or activated sulfonamide results in Formula XVII in which R 7 is a sulfonamino.
  • Treatment of a compound of the Formula XVI with an activated heterocycle results in a compound of Formula XVII in which R 7 is a heterocyclic amino.
  • Treatment of a compound of the Formula XVI with an activated heteroaryl results in a compound of Formula XVII in which R 7 is a heteroaryl amino.
  • Treatment of a compound of Formula XVI with a carbonate, chloroformate, or cyanoformate gives compounds of Formula XVII in which R 7 is a carbamate.
  • Treatment of a compound of Formula XVI with a thioester gives compounds of Formula XVII in which R 7 is thioacylamino.
  • Treatment of a compound of Formula XVI with a phosphoryl chloride or phosphoramidate gives compounds of Formula XVII in which R 7 is phosphonamino.
  • Treatment of a compound of Formula XVI with an imidate gives compounds of Formula XVII in which R 7 is iminoamino.
  • Treatment of a compound of Formula XVI with a thioisocyanate gives compounds of Formula XVII in which R 7 is thioureido.
  • the modifying agent is an activated ester.
  • the modifying agent is wherein each of R aa1 , R aa2 , and R aa3 is an amino acid side chain or a protected form of an amino acid side chain;
  • R 36 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
  • X is an activating group.
  • X is an aryloxy group.
  • X is pentafluorophenoxy.
  • Compounds of Formulas XXI, XXII and XXIII can be prepared from the corresponding peptide or amino acid upon treatment with an activating agent such as anhydrides, chloroformates, pentafluorophenol/dicyclohexylcarbodiimide, N′,N′-carbonyldiimidazole, hydroxybenzotriazole or N-hydroxysuccinimide.
  • the peptides can be prepared by any standard peptide procedure. For an overview of some standard peptide formation procedures see Vogel's Textbook of Practical Organic Chemistry, 5 th Ed ., eds. B. S. Furniss, A. J. Hannaford; P. W. G. Smith; A. R.
  • Tatchell New York: John Wiley and Sons, Inc.
  • 1989 pp750-763 and Introduction to Organic Chemistry, 2 nd Ed . by A. Streitwieser, Jr. and C. H. Heathcock (New York: MacMillan Publishing Co., Inc.), pp 954-962.
  • Other methods that are useful for the preparation of peptides of the present invention involve synthesis on a solid support. Specific examples of such procedures are detailed in the examples (vide infra).
  • Step (h) Removal of the protecting group(s) from the protected Formula I compound (the compound of Formula XVII) results in the formation of the compound of Formula Ia (step (h)) wherein, R 1 , R 4 , R 5 , R 6 , and R 7 are as previously described; R 2a is methyl or —CH 2 CH 2 CH 2 NH 2 , and R 3a is a methyl or —CH 2 CH 2 CH 2 CH 2 NH 2 .
  • Removal of the amino protecting group can be accomplished according to procedures described in Greene (vide supra). As those skilled in the art will recognize, the choice of amino protecting group employed in the first step of the process will dictate the reagents and procedures used in removing said amino protecting group.
  • the modifying agent contains one or more protecting group(s)
  • said protecting group(s) must also be removed.
  • the choice of the protecting group(s) utilized on the modifying agent substituent(s) will dictate the reagents and procedures used in removing said protecting group(s).
  • the protecting groups may be removed in a single step. However, when the protecting group(s) are incompatable multiple steps may be required to remove all of the protecting groups.
  • R 7 or the modifying agent of step (i) contain substituents that are incompatible with the reaction conditions under which the compound of Formula I is formed, said substituents will have to be protected prior to step (i). Suitable protecting groups and methods of making them can be found in Greene (vide supra).
  • R 7 , and the modifying agent of step (i) contain protecting group(s), said protecting group(s) may be removed.
  • the choice of the protecting group(s) utilized on R 7 and the modifying agent substituent(s) will dictate the reagents and procedures used in removing said protecting group(s).
  • the protecting groups may be removed in a single step. However, when the protecting group(s) are incompatable multiple steps may be required to remove all of the protecting groups.
  • An alternate procedure for preparing compounds of Formula I wherein at least one of R 2 and R 3 is other than methyl and each of R 8 and R 9 is other than NH 2 comprises the steps of:
  • Suitable agents for the deacylation of compounds of Formula XXIV are enzymatic deacylated agents (vide supra).
  • Step (d) Removal of the tryptophan amino acid residue from the terminal amino compound of Formula XXV leads to the formation of the compound of Formula XXVI (step (d)).
  • Methods for removal of the tryptophan amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the tryptophan amino acid residue is under Edman degradation conditions (vide supra).
  • Step (e) Removal of the terminal amino acid residue from the compound of Formula XXVI leads to the formation of the desdipeptide compound of Formula XXVII (step (e)).
  • Methods for removal of the terminal amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • Step (f) Removal of the terminal amino acid residue from the compound of Formula XXVII leads to the formation of the depsipeptide core compound of Formula XXVIII (step (f)).
  • Methods for removal of the terminal amino acid residue are known to those skilled in the art.
  • a preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • protecting groups may be removed.
  • the protecting groups may be removed in a single step.
  • multiple steps may be required to remove all of the protecting groups.
  • R 39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XIII, as described in Scheme VI, or by compound XXV as described in Scheme VII. Procedure E
  • R 18 , R 19 , and R 20 are as previously described and R 39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XIV, as described Scheme VIII, or by compound XXVI as described in Scheme IX. Procedure F
  • each of R 18 , and R 19 is as previously described and R 39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XV, as described Scheme X, or by compound XXVII as described in Scheme XI.
  • the depsipeptide compounds of Formula I may be synthesized on a solid support (Scheme XII, Scheme XIII and Scheme XV).
  • step 1 an N-protected- ⁇ -methyl glutamic acid-O-allyl ester or a protected glutamic acid-O-allyl ester is coupled to a resin to give Compound 101, wherein R 6 is as described previously.
  • a resin or solid support such as, but not limited to, Wang, HMPA, Safety Catch, Rink Acid, 2-chlorotrityl-chloride resin, trityl-chloride resin, 4-methyltrityl-chloride resin, 4-methoxytrityl-chloride resin or PAM resin may be used in this reaction.
  • step 1 a N-protected-glycine or a sarcosine is coupled to a resin to give Compound 104 wherein R 1 is as described previously and P 8 is an amino protecting group.
  • R 1 is as described previously and P 8 is an amino protecting group.
  • the choice of resin used in step 1 is dependent upon the nature of the amino acid that is coupled in steps 2-6. If the amino acid side chains contain protecting groups, a resin must be chosen such that the protecting groups remain intact when the resin is removed from the peptide in step 7.
  • Resins that can be cleaved while preserving the protecting groups of peptides include, but are not limited to, Safety Catch, Rink Acid, 2-chlorotrityl-chloride resin, trityl-chloride resin, 4-methyltrityl-chloride resin, 4-methoxytrityl-chloride resin or PAM resin.
  • R 43 is a group capable of being converted to an amino group.
  • R 43 may be azido, a protected amino phthalimido or nitro.
  • the peptide fragments 103 and 112 are coupled to yield the resin bound peptide 113.
  • Deprotection of the P 9 protecting group and O-allyl ester, followed by cyclization affords a resin-bound depsipeptide 114.
  • Cleavage of the depsipeptide from the resin followed by deprotection of any remaining protecting groups yields compounds of Formula I (Scheme XVI).
  • compound 105 can be used in place of compound 108 (Scheme XV).
  • Compound 105 is coupled with Compound 110 to give Compound 115; removed from the resin to give Compound 116; coupled with Compound 103 to give Compound 117; then deprotected and cyclized to yield a resin bound depsipeptide (118) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
  • compound 106 can be used in place of compound 108 (Scheme XVII).
  • Compound 106 is coupled with Compound 110 to give Compound 119; removed from the resin to give Compound 120; coupled with Compound 103 to give Compound 121; then deprotected and cyclized to yield a resin bound depsipeptide (122) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
  • compound 107 can be used in place of compound 108 (Scheme XVIII).
  • Compound 106 is coupled with Compound 110 to give Compound 123; removed from the resin to give Compound 124; coupled with Compound 103 to give Compound 125; then deprotected and cyclized to yield a resin bound depsipeptide (126) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
  • Suitable protecting groups can be any amino protecting group useful in peptide synthesis. Such pairings of protecting groups are well known. See, e.g., “Synthesis Notes” in the Novabiochem Catalog and Peptide Synthesis Handbook (1999), pages S1-S93 and references cited therein.
  • the compounds of the present invention can also be prepared by recombinant methods.
  • a modified non-ribosomal peptide synthetase of daptomycin is introduced into a cell capable of producing a compound of Formula I an d the cell is cultured to form a compound of Formula I.
  • the non-ribosomal peptide synthetases of daptomycin as well as modifications of these synthetases have been reported (see International Patent Application Serial Number 02/059,322).
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-threonine 2 mL of a 0.5 molar solution in N-methylpyrolidine
  • 1,3-diisopropylcarbodiimide 2 mL of a 0.5 molar solution in N-methylpyrolidine
  • 1-hydroxy-benzotriazole 2 mL of a 0.5 molar solution in N-methylpyrolidine
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-aspartic acid ⁇ -tert-butyl ester (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to compound 3.
  • the mixture was shaken for one hour, filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-tryptophan (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin.
  • the reaction mixture was shaken for one hour, then filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 8.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-serine-tert-butyl ether (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 11.
  • the reaction mixture was shaken for one hour, then filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 12.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-glycine ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 13.
  • the reaction mixture was shaken for one hour, then filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 14.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-aspartic acid ⁇ -tert-butyl ester ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 15.
  • the reaction mixture was shaken for one hour, filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 16.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-alanine ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 17.
  • the reaction mixture was shaken for one hour, filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 18.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-aspartic acid ⁇ -tertbutyl ester ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 19. The reaction mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 20.
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-N ⁇ -(tertbutoxycarbonyl)-L-ornithine (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 21.
  • the reaction mixture was shaken for one hour, then filtered and the coupling was repeated.
  • the reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3 ⁇ 6 mL), methanol (3 ⁇ 6 mL), and again with N-methylpyrolidine (3 ⁇ 6 mL) to give compound 22.
  • Resin peptide 1 (2 g) was added to a solution of the pentafluorophenyl ester of decanoic acid 24 (440 mg, for the preparation of compound 24 see Example 6, Reaction 1) in dichloromethane. The mixture was shaken for 17 hours, filtered, and the reaction was judged to be incomplete using the Kaiser Test (vide supra). Decanoic acid (517 mg), 1-hydroxy-benzotriazole (446 mg), and 1,3-diisopropylcarbodiimide (438 ⁇ L) were dissolved in N-methylpyrolidine (8 mL) and stirred for one hour.
  • the dried resin 27 was placed under an argon atmosphere, and treated with a solution of tetrakis-(triphenylphosphine)palladium(0) (19 mg) in dichloromethane (1.47 mL), acetic acid (74 ⁇ L), and N-methylmorpholine (37 ⁇ L). The mixture was shaken for 4 hours at ambient temperature, filtered, and the solid was washed with two times with N-methylmorpholine, two times with methanol, and again two times with N-methylmorpholine.
  • the dried resin 28 was suspended in dichloromethane, (4 mL) trifluoroacetic acid, (6 mL) ethanedithiol (250 ⁇ l), and triisopropylsilane (250 ⁇ l), and the reaction mixture was stirred for 3 hours at ambient temperature.
  • the resin was filtered and the combined filtrates were evaporated under reduced pressure. Crude product was then partitioned between diethyl ether (6 mL), and water (3 mL). The aqueous layer was freeze-dried to give crude product.
  • the crude product was purified by reverse phase HPLC (C18 10 uM Jupiter column 250 ⁇ 21.2 mm) eluting with a gradient from 20% acetonitrile 0.5% formic acid: 80% water 0.5% formic acid to 80% acetonitrile 0.5% formic acid: 20% water 0.5% formic acid over 25 minutes.
  • the product bearing fractions were combined and freeze-dried to give the pure product 29 (1.0 mg).
  • N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-isoleucine 95 mg
  • 4-dimethylaminopyridine 6 mg
  • N-methyl-2-chloropyridinium iodide 69 mg
  • Triethylamine 76 ⁇ L
  • Resin lipopeptide 23 200 mg was added to the solution, the flask was flushed again with argon and then shaken for 14 hours. The resulting resin was then filtered and washed well with dichloromethane.
  • the dried resin 31 was placed under an argon atmosphere, and treated with a solution of tetrakis-(triphenylphosphine)palladium(0) (48 mg in dichloromethane (7.63 mL)), acetic acid (0.38 mL), and N-methylmorpholine (0.19 mL). The mixture was shaken for 4 hours at ambient temperature, filtered, and the solid was washed two times with N-methylmorpholine, two times with methanol, and again two times with N-methylmorpholine. The solid resin was suspended in 20% piperidine in N-methylmorpholine (7 mL) for 105 minutes, filtered and the solid was washed well with N-methylmorpholine.
  • the dried resin 32 was suspended in dichloromethane (4 mL), trifluoroacetic acid (6 mL), ethanedithiol (250 ⁇ l), and triisopropylsilane (250 ⁇ l), and stirred for 3 hours at ambient temperature.
  • the reaction mixture was filtered an washed with dichloromethane (2 ⁇ 2 mL) and the combined filtrates were evaporated under reduced pressure.
  • Crude product was then partitioned between diethyl ether (6 mL) and water (3 mL). The aqueous layer was separated and freeze dried to give the crude product 33 (21.5 mgs).
  • the crude product was then purified by reverse phase HPLC (C18 10 uM Jupiter column 250 ⁇ 21.2 mm) eluting with a gradient from 20% acetonitrile 0.5% formic acid: 80% water 0.5% formic acid to 80% acetonitrile 0.5% formic acid: 20% water 0.5% formic acid over 25 minutes.
  • the product bearing fractions were combined and freeze-dried to give the pure product 33 (1.8 mg).
  • Lithium hydroxide mono hydrate (0.59 g) was added to a solution of compound 37 (1.40 g) methanol (15 mL) and water (3 mL) and the reaction mixture was stirred for one hour. The methanol was removed by evaporation and the aqueous solution was acidified to pH 1 with 1 N hydrochloric acid and extracted with ethyl acetate. The organic layers were combined and dried with anhydrous sodium sulphate and evaporated to give the product 38.
  • 1,3-Diisopropylcarbodiimide (121 mg) was added to a solution of the compound 38 (200 mg), and pentafluorophenol (108 mg) in tetrahydrofuran (5 mL) and the reaction mixture was stirred for one hour. The resulting mixture was filtered, the solvent was evaporated and the residue was purified on silica gel. Using 9:1 hexane:ethyl acetate as an eluent gave the faster running impurity and 4:1 hexane:ethyl acetate as an eluent gave the product 34 (80 mg).
  • Compound 39 was prepared from commercially available 40 via the conditions described above as follows: Compound 39 was converted to the corresponding methyl ester under the conditions described in Example 6, Reaction 2. The methyl ester was acylated under the conditions described in Example 6, Reaction 3. The acylated compound was then saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 39 via the conditions described in Example 6, Reaction 5.
  • Decanoyl chloride (0.51 mL) was added to a solution of amino acid methyl ester 43(440 mg) and triethylamine (0.43 mL) cooled to 0° C. in an ice bath. The reaction was allowed to warm to ambient temperature over three hours. The reaction was then poured into ethyl acetate and washed successively with water, and saturated sodium chloride. The organic layers were then dried with anhydrous sodium sulphate and evaporated to give the product 44.
  • Compound 44 was converted to compound 41 via the conditions described in the as follows. Compound 44 was saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 41 via the conditions described in Example 6, Reaction 5.
  • Compound 45 was prepared from commercially available 46 via the conditions described above as follows: Compound 46 was converted to the corresponding methyl ester under the conditions described in Example 6, Reaction 2. The methyl ester was acylated under the conditions described in Example 8, Reaction 2. The acylated compound was then saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 45 via the conditions described in Example 6, Reaction 5.
  • 1,3-Diisopropylcarbodiimide (206 mg) was added to a solution of the compound 56 (340 mg), and pentafluorophenol (227 mg) in dichloromethane (5 mL) and the reaction mixture was stirred for 15 hours. The mixture was quenched with hexane, filtered, and the solvent was evaporated. Purification of the residue on silica gel with 20:1 hexane:ethyl acetate gave the product 53 (490 mg).
  • Compound 63 is then converted to Compound 64 utilizing the conditions described in Example 12, Reaction 1 using methyl iodide in place of iododecane.
  • Diisopropylethylamine (0.5 mL) was added to a solution of commercially available N ⁇ -(9-Fluorenylmethoxycarbonyl)-L-tryptophan (1.23 g), TBTU (0.92 g) and N,N-dimethylformamide (10 mL) and the resulting mixture was shaken for 10 minutes. The solution was then added to resin F, shaken for one hour, filtered, and the solid was washed with N-methylpyrolidine (10 mL) to give compound G.
  • Diisopropylethylamine (0.5 mL) was added to a solution of commercially available decanoic acid (0.50 g), TBTU (0.92 g) and N,N-dimethylformamide (15 mL) and the resulting mixture was shaken for 10 minutes. The solution was then added to the resin H, shaken for one hour, filtered, and the solid was washed with N-methylpyrolidine (10 mL) to give compound I.
  • a preparation of deacylase enzyme was produced from recombinant Streptomyces lividans , which expresses the Actinoplanes utahensis deacylase enzyme.
  • the enzyme in aqueous ethylene glycol (10 mL) was added to a solution of compound 67 (15 g in water; 1.9 L) at pH 8.
  • the reaction mixture was stirred at room temperature for 18 hours and the pH was adjusted to 8 using 1 M sodium hydroxide.
  • the reaction mixture was poured on to Bondesil 40 ⁇ M C8 resin (400 g) that had been prewashed with methanol (1 L) and water (1 L).
  • the product was eluted with 20% acetonitrile in water (1 L) and freeze-dried to give compound 68 as a yellow solid (9.1 g).
  • Phenylisothiocyanate (1 mmol) is added to a suspension of compound 72 (1.0 mmol) in dry N,N′-dimethylformamide (5 mL). The reaction is stirred at ambient temperature for 18 hours, then evaporated to dryness. The residue is titurated with diethyl ether (5 mL) to give the product 73.
  • Tetrakis-(triphenylphosphine)palladium(0) (631 mg) was added to a solution of Compound 75 (631 mg), N-methyl morpholine (631 ⁇ l) in dioxane (10 mL) and 1 N hydrochloric acid (6.31 mL). After stirring for 16 hours the reaction was filtered, and purified by reverse phase HPLC using C18 10 uM Jupiter column 250 ⁇ 21.2 mm, eluting with a gradient from acetonitrile:water:formic acid 30:70:0.1 to acetonitrile:water:formic acid 90:10:0.1 over 25 minutes. Evaporation of the product bearing fractions gave the product 76 (44 mg).
  • MIC minimum inhibitory concentration
  • “++” indicates that the compound has an MIC ( ⁇ g/ml) or ED 50 of greater than 1 ⁇ g/ml or 1 mg/kg, respectively but less than or equal to 10 ⁇ g/ml or ED 50 of 10 mg/kg, respectively;
  • “+” indicates that the compound has an MIC ( ⁇ g/ml) of greater than 10 ⁇ g/ml or an ED 50 of greater than 10 mg/kg.
  • the mouse protection test is an industry standard for measuring the efficacy of a test compound in vivo [for examples of this model see J. J. Clement, et al., Antimicrobial Agents and Chemotherapy, 38 (5), 1071-1078, (1994)]. As exemplified below, this test is used to demonstrate the in vivo efficacy of the compounds of the present invention against bacteria.
  • the in vivo antibacterial activity is established by infecting female CD-1 mice (Charles River Lab, MA) weighing 19-23 g intraperitoneally with Methicillin Resistant S. aureus (MRSA) inoculum.
  • MRSA Methicillin Resistant S. aureus
  • the inoculum is prepared from Methicillin Resistant S. aureus (ATCC 43300).
  • the MRSA inoculum is cultured in Mueller-Hinton (MH) broth at 37° C. for 18 hours.
  • MH Mueller-Hinton
  • the optical density at 600 nm (OD 600 ) is determined for a 1:10 dilution of the overnight culture.
  • Bacteria (8 ⁇ 10 8 cfu) is added to 20 ml of phosphate buffered saline (Sigma P-0261) containing 5% hog gastric mucin (Sigma M-2378). All animals are injected with 0.5 ml of the inoculum, equivalent to 2 ⁇ 10 7 cfu/mouse, which is the dose causing ⁇ 100% death of the animals without treatment.
  • Group 6 animals receive test compound sc at 10 mg/kg (or the highest therapeutic dose of a given compound) only for monitoring acute toxicity. These injections are repeated once at 4 hours after the inoculation for the respective groups. The injection volume at each time is 10 ml per kilogram of body weight. The 50% protective dose (PD 50 ) is calculated on the basis of the number of mice surviving 7 days after inoculation.

Abstract

The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. patent application Ser. No. 10/213,389 filed, Aug. 6, 2002, which claims priority from U.S. Provisional Application 60/310,313 filed Aug. 6, 2001.
    • FIELD OF THE INVENTION
  • The present invention relates to novel depsipeptides compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial agents. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.
    • BACKGROUND OF THE INVENTION
  • The rapid increase in the incidence of gram-positive infections—including those caused by resistant bacteria—has sparked renewed interest in the development of novel classes of antibiotics. A class of compounds that have shown potential as useful antibiotic agents is the cyclic depsipeptides. A notable member of the cyclic depsipeptides is the A-21978C lipopeptides described in, for example, U.S. Pat. RE 32,333; RE 32,455; RE 32,311; RE 32,310; U.S. Pat. Nos. 4,482,487; 4,537,717; and 5,912,226 and International Patent Applications WO01/44272; WO01/44274; and WO01/44271. Additionally, the A54145 class of compounds described in U.S. Pat. Nos. 4,994,270; 5,039,789; and 5,028,590 have also been shown to possess antibiotic activity.
  • Daptomycin, also known as LY 146032, is comprised of an n-decanoyl side chain linked to the N-terminal tryptophan of a three-amino acid chain linked to a cyclic 10-amino acid peptide. Daptomycin has potent bactericidal activity in vitro and in vivo against clinically relevant gram-positive bacteria that cause serious and life-threatening diseases. These bacteria include resistant pathogens, such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide intermediate susceptible Staphylococcus aureus (GISA), vancomycin-resistant Staphylococcus aureus (VRSA), coagulase-negative staphylococci (CNS), and penicillin-resistant Streptococcus pneumoniae (PRSP), for which there are few therapeutic alternatives. See, e.g., Tally et al., 1999, Ext. Opin. Invest. Drugs 8:1223-1238.
  • Despite the promise that existing antibacterial agents have shown, the need for novel antibiotics continues. Many pathogens have been repeatedly exposed to commonly used antibiotics. This exposure has led to the selection of variant antibacterial strains resistant to a broad spectrum of antibiotics. The loss of potency and effectiveness of an antibiotic caused by resistant mechanisms renders the antibiotic ineffective and consequently can lead to some life-threatening infections that are virtually untreatable. As new antibiotics come to market pathogens may develop resistance or intermediate resistance to these new drugs, effectively creating a need for a stream of new antibacterial agents to combat these emerging strains. In addition compounds that exhibit bactericidal activity offer advantages over present bacteriostatic compounds. Thus, novel antibacterial agents would be expected to be useful to treat not only “natural” pathogens, but also intermediate drug resistant and drug resistant pathogens because the pathogen has never been exposed to the novel antibacterial agent. New antibacterial agents may exhibit differential effectiveness against different types of pathogens.
    • SUMMARY OF THE INVENTION
  • The present invention provides novel compounds that have antibacterial activity against a broad spectrum of bacteria, including drug-resistant bacteria, and processes for making these compounds.
  • The present invention provides, in one aspect, compounds of Formula I:
    Figure US20060194714A1-20060831-C00001
    and salts thereof; wherein:
  • (a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • (b) each R1 and R6 is independently hydrido or methyl;
  • (c) R2 is methyl or —CH2CH2CH2R8;
  • (d) R3 is methyl or —CH2CH2CH2CH2R9;
  • (e) R4 is hydrido or methoxy;
  • (f) R5 is hydroxy or carboxyamino;
  • (g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
  • (h) provided that
      • (1) when R2 is —CH2CH2CH2R8, R7 is other than
        Figure US20060194714A1-20060831-C00002
        • wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
      • (2) when R2 is methyl, R7 is other than
        Figure US20060194714A1-20060831-C00003
        • wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl.
  • In another aspect, the present invention also provides pharmaceutical compositions including compounds of Formula I and methods of use thereof.
  • In a further aspect the present invention provides a process for preparing the compounds of Formula I.
  • In yet a further aspect, the invention provides compounds useful as intermediates for the preparation of the compounds of Fomula I.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions
  • The term “activating group” denotes a group that when adjacent to a carbonyl group activates the carbonyl group to attack by a nucleophilic amine, resulting in the loss of the activating group and the formation of an amide bond. Examples of activating groups are aryloxy, acyloxy, imidazolyl
    Figure US20060194714A1-20060831-C00004
  • Preferred activating groups are aryloxy groups. The most preferred activating group is pentafluorophenoxy.
  • The term “acyl” denotes a carbonyl radical attached to an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycyl, aryl or heteroaryl group, examples including, without limitation, such radicals as acetyl and benzoyl. Subsets of the term acyl are (1) “unsubstituted alkanoyl” which is defined as carbonyl radical attached to an unsubstituted alkyl group and (2) “unsubstituted alkenoyl” which is defined as carbonyl radical attached to an unsubsituted alkenyl group.
  • The term “acylamino” is defined as a nitrogen radical adjacent to an acyl group.
  • The term “acyloxy” denotes an oxygen radical adjacent to an acyl group.
  • The term “alkenyl” is defined as linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon double bond. One or more hydrogen atoms can also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. The double bond portion(s) of the unsaturated hydrocarbon chain may be either in the cis or trans configuration. Examples of alkenyl groups include, without limitation, ethylenyl or phenyl ethylenyl. A subset of term alkenyl is “unsubstituted alkenyl” which is defined as an alkenyl group that bears no substituent groups.
  • The term “alkoxy” denotes oxygen radical substituted with an alkyl, cycloalkyl or heterocyclyl group. Examples include, without limitation, methoxy, tert-butoxy, benzyloxy and cyclohexyloxy.
  • The term “alkyl” is defined as a linear or branched, saturated radical having one to about twenty carbon atoms unless otherwise specified. The term “lower alkyl” is defined as an alkyl group containing 1-4 carbon atoms. One or more hydrogen atoms can also be replaced by a substitutent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. Examples of alkyl groups include, without limitation, methyl, butyl, tert-butyl, isopropyl, trifluoromethyl, nonyl, undecyl, octyl, dodecyl, methoxymethyl, 2-(2′-aminophenacyl), 3-indolylmethyl, benzyl, and carboxymethyl. Subsets of the term alkyl are (1) “unsubstituted alkyl” which is defined as an alkyl group that bears no substituent groups (2) “substituted alkyl” which denotes an alkyl radical in which one or more hydrogen atoms is replaced by a substitutent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido and (3) “selected substituted alkyl” which denotes an alkyl radical in which (a) one proton is replaced by a group selected from hydroxy, carboxy, C1-C8 alkoxy, or (b) one to three protons is replaced by a halo substituent.
  • The term “alkylidenyl” is defined as a carbon radical of the formula
    Figure US20060194714A1-20060831-C00005
    wherein Rx and Rx1 are independently selected from hydrido or C7-C17 unsubstituted alkyl, wherein the total number of carbons from Rx and Rx1 does not exceed 17.
  • The term “alkynyl” denotes linear or branched radicals having from two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. One or more hydrogen atoms can also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. An example of alkynyl group includes, without limitation, propynyl.
  • The term “amino” is defined as an NH2 radical.
  • The term “amino acid resisue” denotes a compound of the formula
    Figure US20060194714A1-20060831-C00006
    wherein Raa is an amino acid side chain.
  • The term “amino acid side chain” denotes any side chain (R group) from a naturally-occurring or synthetic amino acid. For example, 3-indolylmethyl could also be called a tryptophan side chain.
  • The term “2-(2′-aminophenacyl)” refers to a radical of the formula
    Figure US20060194714A1-20060831-C00007
  • The term “amino protecting group” refers to any chemical compound that may be used to prevent an amino group on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule. Numerous amino protecting groups are known to those skilled in the art and examples can be found in “Protective Groups in Organic Synthesis” by Theodora W. Greene, John Wiley and Sons, New York, 1981. Examples of amino protecting groups include phthalimido, trichloroacetyl, STA-base, benzyloxycarbonyl, t-butoxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, adamantyloxycarbonyl, chlorobenzyloxycarbonyl, nitrobenzyloxycarbonyl or the like. Preferred amino protecting groups are “carbamate amino protecting groups” which are defined as an amino protecting group that when bound to an amino group forms a carbamate. Preferred amino carbamate protecting groups are allyloxycarbonyl (alloc), carbobenzyloxy (CBZ), and tert-butoxycarbonyl protecting groups.
  • The term “aryl” or “aryl ring” is defined as an aromatic radical in a single or fused carbocyclic ring system, having from five to fourteen ring members. In a preferred embodiment, the ring system has from six to ten ring members. One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. Examples of aryl groups include, without limitation, phenyl, naphthyl, biphenyl, terphenyl.
  • The term “aryloxy” denotes oxy-containing radicals substituted with an aryl or heteroaryl group. Examples include, without limitation, phenoxy.
  • The term “carbamoyl” denotes a nitrogen radical of the formula
    Figure US20060194714A1-20060831-C00008
    wherein Rx2 is selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl and Rx3 is selected from alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl
  • The term “carboalkoxy” is defined as a carbonyl radical adjacent to an alkoxy or aryloxy group.
  • The term “carboxy” denotes a COOH radical.
  • The term “carboxyamino” denotes a CONH2 radical.
  • The term “carboxyamido” is defined as a carbonyl radical adjacent to a monosubstituted amino or disubstituted amino group.
  • The term “α-carboxy amino acid side chain” is defined as a carbon radical of the formula
    Figure US20060194714A1-20060831-C00009
  • wherein Rx4 is defined as an amino acid side chain.
  • The term “carboxymethyl” denotes a CH2CO2H radical.
  • The term “cycloalkyl” or “cycloalkyl ring” denotes a saturated or partially unsaturated carbocyclic ring in a single or fused carbocyclic ring system having from three to twelve ring members. In a preferred embodiment, a cycloalkyl is a ring system having three to seven ring members. One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. Examples of a cycloalkyl group include, without limitation, cyclopropyl, cyclobutyl, cyclohexyl, and cycloheptyl.
  • The term “disubstituted amino” is defined as a nitrogen radical containing two substituent groups independently selected from, alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. Preferred disubstituted amino radicals are “lower disubstituted amino” radicals, whereby the substituent groups are lower alkyl. Also preferred disubstituted amino radicals are amino radicals wherein one substituent is a lower alkyl group and the other substituent is an α-carboxy amino acid side chain.
  • The group “Fmoc” is a 9-fluorenylmethoxycarbonyl group.
  • The term “guanidino” is defined as a nitrogen radical of the Formula
    Figure US20060194714A1-20060831-C00010
  • wherein each of Rx5, Rx7 and Rx8 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and Rx6 is selected from alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • The term “halo” denotes a bromo, chloro, fluoro or iodo radical.
  • “Heteroaryl” or “heteroaryl ring” is defined as an aromatic radical which contain one to four hetero atoms or hetero groups selected from O, N, S, or SO in a single or fused heterocyclic ring system, having from five to fifteen ring members. In a preferred embodiment, the heteroaryl ring system has from six to ten ring members. One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. Examples of heteroaryl groups include, without limitation, pyridinyl, thiazolyl, thiadiazoyl, isoquinolinyl, pyrazolyl, oxazolyl, oxadiazoyl, triazolyl, and pyrrolyl groups.
  • The term “heterocyclyl,” “heterocyclic” or “heterocyclyl ring” denotes a saturated or partially unsaturated ring containing one to four hetero atoms or hetero groups selected from O, N, NH, N (lower alkyl), S, SO or SO2, in a single or fused heterocyclic ring system having from three to twelve ring members. In a preferred embodiment, a heterocyclyl is a ring system having three to seven ring members. One or more hydrogen atoms may also be replaced by a substituent group selected from acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amino, aryl, aryloxy, carbamoyl, carboalkoxy, carboxy, carboxyamido, carboxyamino, cyano, disubstituted amino, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, monosubstituted amino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonyl, thio, thioacylamino, thioureido, or ureido. Examples of a heterocyclyl group include, without limitation, morpholinyl, piperidinyl, and pyrrolidinyl.
  • The term “hydrido” is defined as a single hydrogen atom (H).
  • The term “iminoamino” denotes a nitrogen radical of the formula:
    Figure US20060194714A1-20060831-C00011
  • wherein each of Rx9 and Rx11 is independently selected from a hydrido, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group; and Rx10 is selected from an alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group.
  • The term “modifying agent” is defined as (a) a nucleophilic acceptor or (b) an aldehyde or ketone that reacts with an amine-under reductive conditions to form an alkylated amine.
  • The term “monosubstituted amino” denotes a nitrogen radical containing a hydrido group and a substituent group selected from alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. Preferred monosubstituted amino radicals are “lower monosubstituted amino” radicals, whereby the substituent group is a lower alkyl group. More preferred monosubstituted amino radicals are amino radicals containing an α-carboxy amino acid side chain.
  • The term “nucleophilic acceptor” is defined as a compound that is susceptible to nucleophilic attack by a primary or secondary amine. Examples of nucleophilic acceptors include, without limitation, isocyanates, isothiocyanates, activated esters, acid chlorides, sulfonyl chlorides, activated sulfonamides, activated heterocycles, activated heteroaryls, chloroformates, cyanoformates, thioesters, phosphoryl chlorides, phosphoramidates, imidates, and lactones.
  • The term “phosphonamino” is defined as a nitrogen radical of the Formula:
    Figure US20060194714A1-20060831-C00012
    wherein Rx12 is selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl; wherein each of Rx13 and Rx14 is independently selected from alkyl, alkoxy, aryl, aryloxy, cycloalkyl, heteroaryl and heterocyclyl.
  • The term “sulfinyl” denotes a tetravalent sulfur radical substituted with an oxo substituent and a second substituent selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl group.
  • The term sulfonamino is defined as an amino radical of the formula:
    Figure US20060194714A1-20060831-C00013
  • wherein Rx15 is selected from a hydrido, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group; and Rx16 is selected from alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group.
  • The term “sulfonyl” denotes a hexavalent sulfur radical substituted with two oxo substituents and a third substituent selected from alkyl, cycloalkyl, heterocyclyl aryl, or heteroaryl.
  • The term “thio” is defined as a radical containing a substituent group independently selected from hydrido, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, attached to a divalent sulfur atom, such as, methylthio and phenylthio.
  • The term “thioacylamino” denotes an amino radical of the formula
    Figure US20060194714A1-20060831-C00014
  • wherein Rx17 is selected from a hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and wherein Rx18 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • The term “thioureido” is defined as a sulfur radical of the formula
    Figure US20060194714A1-20060831-C00015
  • wherein each of Rx19 and Rx20 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and Rx21 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • The group trityl is a triphenylmethyl group.
  • The term “ureido” is defined as a nitrogen radical of the formula
    Figure US20060194714A1-20060831-C00016
  • wherein each of Rx21 and Rx22 is independently selected from hydrido, alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group; and Rx23 is selected from an alkyl, aryl, cycloalkyl, heteroaryl or heterocyclyl group.
  • The salts of the compounds of the invention include acid addition salts and base addition salts. In a preferred embodiment, the salt is a pharmaceutically acceptable salt of the compound of Formula I. The term “pharmaceutically acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared from an inorganic acid or an organic acid. Examples of such inorganic acids include, without limitation, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include, without limitation, formic, acetic, propionic, succinic, glycolic, gluconic, maleic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, β-hydroxybutyric, malonic, galactic, and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of the invention include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine and procaine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by treating, for example, the compound of the invention with the appropriate acid or base.
  • The compounds of the invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The compounds of the invention can be utilized in the present invention as a single isomer or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., nonsuperimposable stereochemical isomers, can be separated by conventional means such as chromatography, distillation, crystallization or sublimation. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids include, without limitation, tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid. The mixture of diastereomers can be separated by crystallization followed by liberation of the optically active bases from the optically active salts. An alternative process for separation of optical isomers includes the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to obtain the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • The invention also embraces isolated compounds. An isolated compound refers to a compound which represents at least 10%, preferably at least 20%, more preferably at least 50% and most preferably at least 80% of the compound present in the mixture. In a preferred embodiment, the compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound exhibits a detectable (i.e. statistically significant) antimicrobial activity when tested in conventional biological assays such as those described herein.
  • Depsipeptide Compounds
  • In one aspect, the invention provides compounds of Formula I
    Figure US20060194714A1-20060831-C00017
    and salts thereof; wherein:
  • (a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • (b) each R1 and R6 is independently hydrido or methyl;
  • (c) R2 is methyl or —CH2CH2CH2R8;
  • (d) R3 is methyl or —CH2CH2CH2CH2R9;
  • (e) R4 is hydrido or methoxy;
  • (f) R5 is hydroxy or carboxyamino;
  • (g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
  • (h) provided that
      • (1) when R2 is —CH2CH2CH2R8, R7 is other than
        Figure US20060194714A1-20060831-C00018
        • wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, and phosphonamino;
      • (2) when R2 is methyl, R7 is other than
        Figure US20060194714A1-20060831-C00019
        • wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl.
  • Preferably R7 is
    Figure US20060194714A1-20060831-C00020
      • wherein each of Raa, Raa2 and Raa3 is independently an amino acid side chain and wherein R13 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
  • In one embodiment of the invention, R is 2-(2′-aminophenacyl); each of R1 and R4 is hydrido; R2 is —CH2CH2CH2R8; each of R3 and R6 is methyl; and R5 is hydroxyl. This embodiment provides a compound of Formula II.
    Figure US20060194714A1-20060831-C00021
  • In another embodiment of the invention, R is isopropyl or 2-butyl; each of R1 and R2 is methyl; R3 is —CH2CH2CH2CH2R9; R4 is methoxy, and R5 carboxyamino. This embodiment gives a compound of Formula III.
    Figure US20060194714A1-20060831-C00022
    wherein R14 is hydrido or methyl.
  • Table I provides exemplary compounds of Formula II.
    TABLE I
    Compounds of Formula II
    R7 R8
    Figure US20060194714A1-20060831-C00023
         		NH2
    Figure US20060194714A1-20060831-C00024
         		NH2
    Figure US20060194714A1-20060831-C00025
         		NH2
    Figure US20060194714A1-20060831-C00026
         		NH2
    Figure US20060194714A1-20060831-C00027
         		NH2
    Figure US20060194714A1-20060831-C00028
         		NH2
    Figure US20060194714A1-20060831-C00029
         		NH2
    Figure US20060194714A1-20060831-C00030
         		NH2
    Figure US20060194714A1-20060831-C00031
         		NH2
    Figure US20060194714A1-20060831-C00032
         		NH2
    Figure US20060194714A1-20060831-C00033
         		NH2
    Figure US20060194714A1-20060831-C00034
         		NH2
    Figure US20060194714A1-20060831-C00035
         		NH2
    Figure US20060194714A1-20060831-C00036
         		NH2
    Figure US20060194714A1-20060831-C00037
         		NH2
    Figure US20060194714A1-20060831-C00038
         		NH2
    Figure US20060194714A1-20060831-C00039
         		NH2
    Figure US20060194714A1-20060831-C00040
         		NH2
    Figure US20060194714A1-20060831-C00041
         		NH2
    Figure US20060194714A1-20060831-C00042
         		NH2
    Figure US20060194714A1-20060831-C00043
         		NH2
    Figure US20060194714A1-20060831-C00044
         		NH2
    Figure US20060194714A1-20060831-C00045
         		NH2
    Figure US20060194714A1-20060831-C00046
         		NH2
    Figure US20060194714A1-20060831-C00047
         		NH2
  • Wherein R7** is an amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino and each of Raa4, Raa5, and Raa6 is independently an amino acid side chain.
  • Table II provides exemplary compounds of Formula III.
    TABLE II
    Compounds of Formula III
    R7 R9
    Figure US20060194714A1-20060831-C00048
         		NH2
    Figure US20060194714A1-20060831-C00049
         		NH2
    Figure US20060194714A1-20060831-C00050
         		NH2
    Figure US20060194714A1-20060831-C00051
         		NH2
    Figure US20060194714A1-20060831-C00052
         		NH2
    Figure US20060194714A1-20060831-C00053
         		NH2
    Figure US20060194714A1-20060831-C00054
         		NH2
    Figure US20060194714A1-20060831-C00055
         		NH2
    Figure US20060194714A1-20060831-C00056
         		NH2
    Figure US20060194714A1-20060831-C00057
         		NH2
    Figure US20060194714A1-20060831-C00058
         		NH2
    Figure US20060194714A1-20060831-C00059
         		NH2
    Figure US20060194714A1-20060831-C00060
         		NH2
    Figure US20060194714A1-20060831-C00061
         		NH2
    Figure US20060194714A1-20060831-C00062
         		NH2
    Figure US20060194714A1-20060831-C00063
         		NH2
    Figure US20060194714A1-20060831-C00064
         		NH2
    Figure US20060194714A1-20060831-C00065
         		NH2
    Figure US20060194714A1-20060831-C00066
         		NH2
    Figure US20060194714A1-20060831-C00067
         		NH2
    Figure US20060194714A1-20060831-C00068
         		NH2
    Figure US20060194714A1-20060831-C00069
         		NH2
    Figure US20060194714A1-20060831-C00070
         		NH2
    Figure US20060194714A1-20060831-C00071
         		NH2
    Figure US20060194714A1-20060831-C00072
         		NH2
    Figure US20060194714A1-20060831-C00073
         		NH2
    Figure US20060194714A1-20060831-C00074
         		NH2
    Figure US20060194714A1-20060831-C00075
         		NH2
    Figure US20060194714A1-20060831-C00076
         		NH2
    Figure US20060194714A1-20060831-C00077
         		NH2
    Figure US20060194714A1-20060831-C00078
         		NH2
    Figure US20060194714A1-20060831-C00079
         		NH2
    Figure US20060194714A1-20060831-C00080
         		NH2
    Figure US20060194714A1-20060831-C00081
         		NH2
    Figure US20060194714A1-20060831-C00082
         		NH2
    Figure US20060194714A1-20060831-C00083
         		NH2
    Figure US20060194714A1-20060831-C00084
         		NH2
    Figure US20060194714A1-20060831-C00085
         		NH2
    Figure US20060194714A1-20060831-C00086
         		NH2
    Figure US20060194714A1-20060831-C00087
         		NH2
    Figure US20060194714A1-20060831-C00088
         		NH2
    Figure US20060194714A1-20060831-C00089
         		NH2
    Figure US20060194714A1-20060831-C00090
         		NH2
    Figure US20060194714A1-20060831-C00091
         		NH2
  • Wherein R7** is an amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino and each of Raa4, Raa5, and Raa6 is independently an amino acid side chain.
  • Intermediates
  • The present invention also provides compounds of the Formula IV that are particularly useful as intermediates for the preparation of the compounds of Formula I.
    Figure US20060194714A1-20060831-C00092
    and salts thereof; wherein:
  • (a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
  • (b) each R1 and R6 is independently hydrido or methyl;
  • (c) R4 is hydrido or methoxy;
  • (d) R5 is hydroxy or carboxyamino;
  • (e) R15 is hydrido,
    Figure US20060194714A1-20060831-C00093
      • wherein: R18 is amino or hydroxy; R19 is hydrido or hydroxy; and R20 is carboxyamino or carboxymethyl
  • (f) R16 is methyl or —CH2CH2CH2R21;
  • (g) R17 is methyl or —CH2CH2CH2CH2R22;
      • wherein each of R21 and R22 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
  • In a preferred embodiment of the invention, each of R21 and R22 is —NHR23, wherein R23 is an amino protecting group. In a more preferred embodiment of the invention, R23 is a carbamate amino protecting group selected from allyloxycarbonyl, carbobenzyloxycarbonyl and tert-butoxycarbonyl. In the most preferred embodiment R23 is allyloxycarbonyl.
  • In a more preferred embodiment, the present invention provides intermediates of the Formulas V, VI, VII, VIII, IX and X that are particularly useful as intermediates for the preparation of the compounds of Formula I.
    Figure US20060194714A1-20060831-C00094
    Figure US20060194714A1-20060831-C00095
    wherein R6 and R14 are as previously defined.
    Figure US20060194714A1-20060831-C00096
    wherein R6 and R14 are as previously defined.
    Figure US20060194714A1-20060831-C00097
    wherein R6 and R14 are as previously defined.
    Pharmaceutical Compositions and Methods of Use Thereof
  • The instant invention provides pharmaceutical compositions or formulations comprising compounds of Formula I, or salts thereof.
  • Compounds of the present invention, preferably compounds of Formula I, or pharmaceutically acceptable salts thereof, can be formulated for oral, intravenous, intramuscular, subcutaneous or parenteral administration for the therapeutic or prophylactic treatment of diseases, particularly bacterial infections. For oral or parenteral administration, compounds of the present invention can be mixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers and the like. The compositions comprising a compound of this invention will contain from about 0.1 to about 99% by weight of the active compound, and more generally from about 10 to about 30%.
  • The pharmaceutical preparations disclosed herein are prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent or eliminate the infection (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. and Goodman and Gilman's The Pharmaceutical Basis of Therapeutics, Pergamon Press, New York, N.Y., the contents of which are incorporated herein by reference, for a general description of the methods for administering various antimicrobial agents for human therapy). The compositions of the present invention, preferably compounds of Formula I, can be delivered using controlled (e.g., capsules) or sustained release delivery systems (e.g., bioerodable matrices). Exemplary delayed release delivery systems for drug delivery that are suitable for administration of the compositions of the invention, preferably of Formula I, are described in U.S. Pat. No. 4,452,775 (issued to Kent), U.S. Pat. No. 5,239,660 (issued to Leonard), U.S. Pat. No. 3,854,480 (issued to Zaffaroni).
  • The pharmaceutically-acceptable compositions of the present invention comprise one or more compounds of the invention, preferably compounds of Formula I, in association with one or more nontoxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants and/or excipients, collectively referred to herein as “carrier” materials, and if desired other active ingredients. The compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid. The compositions may contain croscarmellose sodium, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
  • Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.
  • Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
  • Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. It may also be desirable to add a coloring agent to make the dosage form more aesthetic in appearance or to help identify the product.
  • For oral use, solid formulations such as tablets and capsules are particularly useful. Sustained release or enterically coated preparations may also be devised. For pediatric and geriatric applications, suspensions, syrups and chewable tablets are especially suitable. For oral administration, the pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a therapeutically-effective amount of the active ingredient. Examples of such dosage units are tablets and capsules. For therapeutic purposes, the tablets and capsules which can contain, in addition to the active ingredient, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants, for example, magnesium stearate, polyethylene glycol, silica, or talc; disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents. Oral liquid preparations generally are in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents. Examples of additives for liquid preparations include acacia, almond oil, ethyl alcohol, fractionated coconut oil, gelatin, glucose syrup, glycerin, hydrogenated edible fats, lecithin, methyl cellulose, methyl or propyl para-hydroxybenzoate, propylene glycol, sorbitol, or sorbic acid.
  • For intravenous (IV) use, a compound of the present invention can be dissolved or suspended in any of the commonly used intravenous fluids and administered by infusion. Intravenous fluids include, without limitation, physiological saline or Ringer's solution. Intravenous administration may be accomplished by using, without limitation, syringe, minipump or intravenous line.
  • Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions or suspensions can be prepared from sterile powders or granules having one or more of the carriers mentioned for use in the formulations for oral administration. The compounds can be dissolved in polyethylene glycol, propylene glycol, ethanol, corn oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • For intramuscular preparations, a sterile formulation of a compound of the present invention, or a suitable soluble salt form of the compound, for example the hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as Water-for-Injection (WFI), physiological saline or 5% glucose. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g., an ester of a long chain fatty acid such as ethyl oleate.
  • A dose of an intravenous, intramuscular or parental formulation of a compound of the present invention may be adminstered as a bolus or by slow infusion. A bolus is a dose that is administered in less than 30 minutes. In a preferred embodiment, a bolus is administered in less than 15 or less than 10 minutes. In a more preferred embodiment, a bolus is administered in less than 5 minutes. In an even more preferred embodiment, a bolus is administered in one minute or less. An infusion is a dose that is administered at a rate of 30 minutes or greater. In a preferred embodiment, the infusion is one hour or greater. In another embodiment, the infusion is substantially constant.
  • For topical use the compounds of the present invention, preferably compounds of Formula I, can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of creams, ointments, liquid sprays or inhalants, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient.
  • For application to the eyes or ears, the compounds of the present invention, preferably compounds of Formula I, can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.
  • For rectal administration the compounds of the present invention, preferably compounds of Formula I, can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.
  • Alternatively, the compounds of the present invention, preferably compounds of Formula I, can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery. In another embodiment, the unit dosage form of the compound can be a solution of the compound or preferably a salt thereof in a suitable diluent in sterile, hermetically sealed ampoules or sterile syringes. The concentration of the compound in the unit dosage may vary, e.g. from about 1 percent to about 50 percent, depending on the compound used and its solubility and the dose desired by the physician. If the compositions contain dosage units, each dosage unit preferably contains from 1-500 mg of the active material. For adult human treatment, the dosage employed preferably ranges from 5 mg to 10 g, per day, depending on the route and frequency of administration.
  • In another aspect, the invention provides a method for inhibiting the growth of microorganisms, preferably bacteria, comprising contacting said organisms with a compound of the present invention under conditions which permit contact of the compound with said organism and with said microorganism. Such conditions are known to one skilled in the art and are exemplified in the Examples. This method involves contacting a microbial cell with a therapeutically-effective amount of compound(s) of the invention, preferably compound(s) of Formula I, in vivo or in vitro.
  • According to this aspect of the invention, the novel compositions disclosed herein are placed in a pharmaceutically acceptable carrier and are delivered to a recipient subject (preferably a human) in accordance with known methods of drug delivery. In general, the methods of the invention for delivering the compositions of the invention in vivo utilize art-recognized protocols for delivering the agent with the only substantial procedural modification being the substitution of the compounds of the present invention, preferably compounds of Formula I, for the drugs in the art-recognized protocols. Likewise, the methods for using the claimed composition for treating cells in culture, for example, to eliminate or reduce the level of bacterial contamination of a cell culture, utilize art-recognized protocols for treating cell cultures with antibacterial agent(s) with the only substantial procedural modification being the substitution of the compounds of the invention, preferably compounds of Formula I, for the agents used in the art-recognized protocols.
  • In one embodiment, the invention provides a method for treating an infection, especially those caused by gram-positive bacteria, in a subject with a therapeutically-effective amount of a compound of the invention. Exemplary procedures for delivering an antibacterial agent are described in U.S. Pat. No. 5,041,567, and PCT patent application number EP94/02552 (publication no. WO 95/05384), the entire contents of which documents are incorporated in their entirety herein by reference. As used herein, the phrase “therapeutically-effective amount” means an amount of a compound of the present invention that prevents the onset, alleviates the symptoms, or stops the progression of a bacterial infection. The term “treating” is defined as administering, to a subject, a therapeutically-effective amount of a compound of the invention both to prevent the occurrence of an infection and to control or eliminate an infection. The term “subject,” as described herein, is defined as a mammal, a plant or a cell culture. In a preferred embodiment, a subject is a human or other animal patient in need of antibacterial treatment.
  • The method comprises administering to the subject an effective dose of a compound of the present invention. An effective dose is generally between about 0.1 and about 100 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof. A preferred dose is from about 0.1 to about 50 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof. A more preferred dose is from about 1 to 25 mg/kg of a compound of the invention or a pharmaceutically acceptable salt thereof. An effective dose for cell culture is usually between 0.1 and 1000 μg/mL, more preferably between 0.1 and 200 μg/mL.
  • Compositions containing the compounds of the invention can be administered as a single daily dose or in multiple doses per day. The treatment regime may require administration over extended periods of time, e.g., for several days or for from two to four weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the patient, the tolerance of the patient to the compound and the microorganism or microorganisms involved in the infection. A method of administration to a patient of daptomycin, another member of the depsipeptide compound class, is disclosed in U.S. Ser. No. 09/406,568, filed Sep. 24, 1999, which claims the benefit of U.S. Provisional Application No. 60/101,828, filed Sep. 25, 1998, and 60/125,750, filed Mar. 24, 1999, the contents of which are herein incorporated by reference.
  • A compound of the present invention may also be administered in the diet or feed of a patient or animal. If administered as part of a total dietary intake, the amount of compound employed can be less than 1% by weight of the diet and preferably no more than 0.5% by weight. The diet for animals can be normal foodstuffs to which the compound can be added or it can be added to a premix.
  • The present invention also provides methods of administering a compound of Formula I or a pharmaceutical composition thereof to a subject in need thereof in an amount that is efficacious in reducing or eliminating the bacterial infection. The compound may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally, vaginally, or by an implanted reservoir, external pump or catheter. The compound may be prepared for opthalmic or aerosolized uses. The compounds of the present invention can be administered as an aerosol for the treatment of pneumonia or other lung-based infections. A preferred aerosol delivery vehicle is an anhydrous or dry powder inhaler. Compounds of Formula I or a pharmaceutical composition thereof may also be directly injected or administered into an abscess, ventricle or joint. Parenteral administration includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, cisternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion. In a preferred embodiment, the compounds of the present invention are administered intravenously, subcutaneously or orally. In a preferred embodiment for administering a compound according to Formula I to a cell culture, the compound may be administered in a nutrient medium.
  • The method of the instant invention may be used to treat a subject having a bacterial infection in which the infection is caused or exacerbated by any type of bacteria, particularly gram-positive bacteria. In one embodiment, a compound of the present invention or a pharmaceutical composition thereof is administered to a patient according to the methods of this invention. In a preferred embodiment, the bacterial infection may be caused or exacerbated by gram-positive bacteria. These gram-positive bacteria include, but are not limited to, methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S. saprophyticus, and coagulase-negative staphylococci), glycopeptide intermediary-susceptible S. aureus (GISA), vancomycin-resistant Staphylococcus aureus (VRSA), penicillin-susceptible and penicillin-resistant streptococci (including Streptococcus pneumoniae, S. pyogenes, S. agalactiae, S. avium, S. bovis, S. lactis, S. sangius and Streptococci Group C, Streptococci Group G and viridans streptococci), enterococci (including vancomycin-susceptible and vancomycin-resistant strains such as Enterococcus faecalis and E. faecium), Clostridium difficile, C. clostridiiforme, C. innocuum, C. perfringens, C. ramosum, Haemophilus influenzae, Listeria monocytogenes, Corynebacterium jeikeium, Bifidobacterium spp., Eubacterium aerofaciens, E. lentum, Lactobacillus acidophilus, L. casei, L. plantarum, Lactococcus spp., Leuconostoc spp., Pediococcus, Peptostreptococcus anaerobius, P. asaccarolyticus, P. magnus, P. micros, P. prevotii, P. productus, Propionibacterium acnes, Actinomyces spp., Moraxella spp. (including M. catarrhalis) and Escherichia spp. (including E. coli).
  • In a preferred embodiment, the antibacterial activity of compounds of Formula I against classically “resistant” strains is comparable to that against classically “susceptible” strains in in vitro experiments. In another preferred embodiment, the minimum inhibitory concentration (MIC) value for compounds according to this invention against susceptible strains is typically the same or lower than that of vancomycin. Thus, in a preferred embodiment, a compound of this invention or a pharmaceutical composition thereof is administered according to the methods of this invention to a patient who exhibits a bacterial infection that is resistant to other compounds, including vancomycin or daptomycin. In addition, unlike glycopeptide antibiotics, depsipeptide compounds such as those disclosed in the present invention, exhibit rapid, concentration-dependent bactericidal activity against gram-positive organisms. Thus, in a preferred embodiment, a compound according to this invention or a pharmaceutical composition thereof is administered according to the methods of this invention to a patient in need of rapidly acting antibiotic therapy.
  • The method of the instant invention may be used for any bacterial infection of any organ or tissue in the body. In a preferred embodiment, the bacterial infection is caused by gram-positive bacteria. These organs or tissue include, without limitation, skeletal muscle, skin, bloodstream, kidneys, heart, lung and bone. The method of the invention may be used to treat, without limitation, skin and soft tissue infections, bacteremia and urinary tract infections. The method of the invention may be used to treat community acquired respiratory infections, including, without limitation, otitis media, sinusitis, chronic bronchitis and pneumonia, including pneumonia caused by drug-resistant S. pneumoniae or H. influenzae. The method of the invention also may be used to treat mixed infections that comprise different types of gram-positive bacteria, or which comprise both gram-positive and gram-negative bacteria. These types of infections include intra-abdominal infections and obstetrical/gynecological infections. The method of the invention also may be used to treat an infection including, without limitation, endocarditis, nephritis, septic arthritis, intra-abdominal sepsis, bone and joint infections. and osteomyelitis. In a preferred embodiment, any of the above-described diseases may be treated using compounds according to this invention or pharmaceutical compositions thereof.
  • The method of the present invention may also be practiced while concurrently administering one or more other antimicrobial agents, such as antibacterial agents (antibiotics) or antifungal agents. In one aspect, the method may be practiced by administering more than one compound according to this invention. In another embodiment, the method may be practiced by administering a compound according to this invention with a lipopeptide compound, such as daptomycin or the lipopeptide compounds described, for example in International Patent Applications WO01/44272; WO01/44274; and WO01/44271.
  • Antibacterial agents and classes thereof that may be co-administered with a compound according to the invention include, without limitation, penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents including sulfonamides, trimethoprim and its combinations and pyrimethamine, synthetic antibacterials including nitrofurans, methenamine mandelate and methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, eveminomycin, glycopeptide, glycylcylcline, ketolides, oxazolidinone; imipenen, amikacin, netilmicin, fosfomycin, gentamicin, cefiriaxone, Ziracin, LY 333328, CL 331002, HMR3647, Zyvox®, Synercid®, Aztreonam, and Metronidazole, Epiroprim, OCA-983, GV-143253, Sanfetrinem sodium, CS-834, Biapenem, A-99058.1, A-165600, A-179796, KA 159, Dynemicin A, DX8739, DU 6681; Cefluprenam, ER35786, Cefoselis, Sanfetrinem celexetil, HGP-31, Cefpirome, HMR-3647, RU-59863, Mersacidin, KP 736, Rifalazil; AM 1732, MEN 10700, Lenapenem, BO 2502A, NE-1530, PR 39, K130, OPC 20000, OPC 2045, Veneprim, PD 138312, PD 140248, CP 111905, Sulopenem, ritipenam acoxyl, RO-65-5788, Cyclothialidine, Sch-40832, SEP-132613, micacocidin A, SB-275833, SR-15402, SUN A0026, TOC 39, carumonam, Cefozopran, Cefetamet pivoxil, and T 3811.
  • Antifungal agents that may be co-administered with a compound according to the invention include, without limitation, Caspofingen, Voriconazole, Sertaconazole, IB-367, FK-463, LY-303366, Sch-56592, Sitafloxacin, DB-289 polyenes, such as Amphotericin, Nystatin, Primaricin; azoles, such as Fluconazole, Itraconazole, and Ketoconazole; allylamines, such as Naftifine and Terbinafine; and anti-metabolites such as Flucytosine. Other antifungal agents include without limitation, those disclosed in Fostel et al., Drug Discovery Today 5:25-32 (2000), herein incorporated by reference. Fostel et al. discloses antifingal compounds including Corynecandin, Mer-WF3010, Fusacandins, Artrichitin/LL 15G256, Sordarins, Cispentacin, Azoxybacillin, Aureobasidin and Khafrefungin.
  • A compound according to this invention may be administered according to this method until the bacterial infection is eradicated or reduced. In one embodiment, a compound of Formula I is administered for a period of time from 2 days to 6 months. In a preferred embodiment, a compound of Formula I is administered for 7 to 56 days. In a more preferred embodiment a compound of Formula I is administered for 7 to 28 days. In an even more preferred embodiment, a compound of Formula I is administered for 7 to 14 days. A compound of Formula I may be administered for a longer or shorter time period if it is so desired.
  • Preparation of Novel Depsipeptides
    • 1. Semisynthetic Process
  • Process for the Preparation of Compounds of Formula I Wherein at Least One of R2 and R3 is Other than Methyl and Each of R8 and R9 is Independently NH2.
  • Procedure A
  • For compounds of Formula I wherein at least one of R2 and R3 is other than methyl and each of R8 and R9 is independently NH2, the process, in accordance with one aspect of the invention, comprises the steps of:
      • (a) providing a depsipeptide derivative of the Formula XI
        Figure US20060194714A1-20060831-C00098
        • wherein: R, R1, R4, R5, R6, R18, R19, and R20 are as previously described; R25 is an alkyl group; R26 is methyl or —CH2CH2CH2NH2; and R27 is methyl or —CH2CH2CH2CH2NH2; or a salt thereof
      • (b) protecting the free amino group(s) of the compound of Formula XI with a protecting group to obtain a protected depsipeptide compound.
      • (c) treating the protected depsipeptide compound obtained in (b) with a deacylating agent to obtain a terminal amino compound;
      • (d) removing the tryptophan amino acid residue of the terminal amino compound obtained in (c) to obtain a destryptophan compound;
      • (e) removing the terminal amino acid residue of the destryptophan compound obtained in (d) to obtain a desdipeptide compound;
      • (f) removing the terminal amino acid residue of the desdipeptide compound obtained in (e) to obtain a depsipeptide core compound;
      • (g) treating the depsipeptide core compound of (f) with a modifying agent; and
      • (h) removing the protecting group from the protected Formula I compound to obtain Formula Ia compound.
  • Procedure A is illustrated in Scheme I.
    Figure US20060194714A1-20060831-C00099
    Figure US20060194714A1-20060831-C00100
    Figure US20060194714A1-20060831-C00101
  • The semisynthetic process, in accordance with one aspect of the invention comprises providing a compound of the Formula XI (step (a)). Compounds of Formula XI can be obtained by methods disclosed in U.S. Pat. RE 32,333; RE 32,455; RE 32,311; U.S. Pat. Nos. 4,482,487; 4,537,717; 4,800,157, 4,874,843; 4,885,243; 5,912,226; 4,994,270; 5,039,789; and 5,028,590; International Patent Application Serial Numbers WO01/44272, WO01/44274, WO01/44271, WO01/53330, and WO02/059,322 each of which is incorporated herein by reference.
  • In a preferred embodiment, the compound of Formula XI is one in which, each of R1 and R4 is hydrido; each of R3 and R6 is methyl; R5 is hydroxyl; R25 is 7-methylnonyl, 9-methyldecyl, 9-methylundecyl, nonyl, decyl or mixtures thereof and R26 is —CH2CH2CH2NH2.
  • In another preferred embodiment, the compound of Formula XI is one in which R is isopropyl or 2-butyl; each of R1 and R2 is methyl; R4 is methoxy, R5 is carboxyamino; R25 is 8-methylnonanoyl, n-decanoyl, or 8-methyldecanoyl; and R27 is —CH2CH2CH2CH2NH2.
  • The free amine of the compound of Formula XI is treated with a protecting group to give a protected depsipeptide compound of Formula XII (step (b)), wherein: R, R1, R4, R5, R6, R18, R19, R20, and R25 are as described previously; R28 is methyl or —CH2CH2CH2NHP; R29 is methyl or —CH2CH2CH2CH2NHP; wherein P is an amino protecting group or a salt thereof.
  • Examples of amino protecting groups and methods for protecting amines with said groups can be found in Protective Groups in Organic Synthesis by Theodora W. Greene, (New York: John Wiley and Sons, Inc.), 1981, hereafter “Greene”, incorporated herein by reference. Preferred amino protecting groups are carbamate amino protecting groups. More preferred amino groups are allyloxycarbonyl (alloc), carbobenzyloxy (CBZ), and tert-butoxycarbonyl protecting groups. The most preferred carbamate amino protecting group is allylyoxycarbonyl. Methods of protecting the amine of daptomycin, A54145 and related lipopeptides can be found in U.S. Pat. RE 32,310; RE 32,311; U.S. Pat. Nos. 4,482,487; 4,524,135, 4,537,717; 5,039,789; and 5,028,590; International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271.
  • The protected depsipeptide compound is then treated with a deacylating agent to form the terminal amino compound of Formula XIII (step (c)). Deacylating agents suitable for the invention are enzymatic deacylating agents. An enzyme which is useful for deacylation of a compound of Formula XII is produced by certain microorganism of the family Actinoplanaceae. Some of these known species and varieties of this family include Actinoplanes philippinensis, Actinoplanes armeniacus, Actinoplanes utahensis, Actinoplanes missouriensis, Spirillospora albida, Streptosporiangium roseum, Streptosporangium vulgare, Streptosporangium roseum var hollandensi, Streptosporangium album, Streptosporangium viridialbum, Amorphosporangium auranticolor, Ampullariella regularis, Ampullariella campanulata, Ampullariella lobata, Ampullariella digitata, Pilimelia terevasa, Pimelia anulata, Planomonospora parontospora, Planomonospora venezuelensis, Planobispora longispora, Planobispora rosea, Dactylosporangium aurantiacum, and Dactylosporangium thailandende.
  • All natural and artificial variants and mutants which are obtained from the Actinoplanacea and which produce the enzyme may be used in this invention.
  • Preferred sources of the deacylation enzyme are Actinoplanes utahensi: NRRL 12052; Actinoplanes missouriensis NRRL 12053; Actinoplanes sp.: NRRL8122, Actinoplanes sp.: NRRL 12065, Streptosporsngium roseum var hollandensis: NRRL 12064, Actinoplanes utahenis ATCC 14539 and Actinoplanes missouriensis ATCC 14538. The more preferred source of deacylation enzyme is the species Actinoplanes utahensi. The most preferred source of deacylation enzyme is one produced from recombinant Streptomyces lividans, which expresses the Actinoplanes utahensis deacylation enzyme as described in J. Ind. Microbiol. Biotechnol. 2000, 24(3) 173-180. This enzyme is also known as echinocandin B deacylase or ECB deacylase.
  • Suitable methods for enzymatic deacylation of compounds of Formula XII can be found in U.S. Pat. Nos. 4,524,135; 4,537,717; 4,482,487; RE 32,310, RE 32,311 U.S. Pat. Nos. 5,039,789 and 5,028590; International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271; each herein incorporated by reference.
  • Removal of the tryptophan amino acid residue from the terminal amino compound of Formula XIII leads to the formation of the compound of Formula XIV (step (d)). Methods for removal of the tryptophan amino acid residue are known to those skilled in the art. A preferred method for removal of the tryptophan amino acid residue is under Edman degradation conditions.
  • The Edman degradation is a well-established reaction known to those skilled in the art (see, for example, P. Edman, 1950, Acta Chem. Scan. 4: 283-93 and P. Edman, 1956, Acta Chem Scan 10: 761-768). In this reaction the terminal NH2 group of a peptide reacts with an isothiocycanate to form a thiourea derivative of the peptide. Upon treatment with acid or base, the thiourea peptide undergoes a cyclization reaction, giving a thiohydantoin and a shorter peptide (see Scheme II).
    Figure US20060194714A1-20060831-C00102
  • wherein R30, R31, and R32, are each an amino acid side chain; and R33 is an aryl or alkyl group.
  • The Edman degradation can be carried out under a variety of conditions. In the first step of the Edman degradation sequence the isothiocyanate reacts with the amine under neutral to mildly basic (pH <9.5) conditions in solvents such as tetrahydrofuran, N,N′-dimethylformamide, dichloromethane, dioxane or ethanol. A variety of isothiocyanates can be used (see K. K. Han et al. Biochemie 1977, 59: 557-576.
  • Subsequent cyclization and cleavage can be accomplished under a variety of conditions. Typically, anhydrous trifluoroacetic acid, heptafluorobutyric acid (see, for example, W. F. Brandt et al., 1976, Z. Physiol. Chem. 357: 1505-1508) or concentrated hydrochloric acid (see, for example, G. E. Tarr, 1977, Methods in Enzymology, 47: 335-337) are used. Mild basic conditions such as triethylamine or N,N-dimethylallyamine/acetic acid (pH ˜9) can also be used (see G. C. Barrett et al., 1985, Tetrahedron Letters 26(36): 4375-4378). For a review of this reaction see K. K. Han, 1985, Int. J. Biochem 17(4): 429-445.
  • In a preferred embodiment, the thiourea peptide (the compound of Formula XVIII) formed upon reaction of the thioisocyanate with a compound of Formula XIII is treated under acidic conditions to provide a compound of Formula XIV. In a more preferred embodiment of the invention, a compound of Formula XVIII is treated with trifluoroacetic acid to give the compound of Formula XIV (Scheme III).
    Figure US20060194714A1-20060831-C00103
  • wherein each of R, R1, R4, R5, R6, R18, R19, R20, R28, R29 and R33 is as described previously.
  • In a preferred embodiment, R33 is phenyl, n-decyl, nonyl or octyl. In a more preferred embodiment, R33 is n-decyl.
  • Removal of the terminal amino acid residue from the compound of Formula XIV leads to the formation of the desdipeptide compound of Formula XV (step (e)). Methods for removal of the terminal amino acid residue are known to those skilled in the art. A preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • In a preferred embodiment, the thiourea peptide (the compound of Formula XIX) formed upon reaction of the thioisocyanate with a compound of Formula XIV, is treated under acidic conditions to provide desdipeptide compound of Formula XV. In a preferred embodiment of the invention, a compound of Formula XIX is treated with trifluoroacetic acid to give the compound of Formula XV (Scheme IV).
    Figure US20060194714A1-20060831-C00104
  • wherein each of R, R1, R4, R5, R6, R18, R19, R20, R28, and R29 is as described previously; and R34 is alkyl or aryl.
  • Removal of the terminal amino acid residue from the compound of Formula XV leads to the formation of the depsipeptide core compound of Formula XVI (step (f)). Methods for removal of the terminal amino acid residue are known to those skilled in the art. A preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • In a preferred embodiment, the thiourea peptide (the compound of Formula XX) formed upon reaction of the thioisocyanate with a compound of Formula XV, is treated under acidic conditions to provide the depsipeptide core compound of Formula XVI. In a preferred embodiment of the invention, a compound of Formula XX is treated with trifluoroacetic acid to give the compound of Formula XVI (Scheme IV A).
    Figure US20060194714A1-20060831-C00105
  • wherein each of R, R1, R4, R5, R6, R18, R19, R20, R28, and R29 is as described previously; and R35 is alkyl or aryl.
  • Treatment of the depsipeptide core compound of Formula XVI with a modifying agent results in the formation of protected Formula I compound (the compound of Formula XVII, step (f)). The reaction of an amine with modifying agents, as defined herein, is well known to those skilled in the art. For example, treatment of a compound of Formula XVI with an isocyanate gives compounds of Formula XVII in which R7 is ureido. Similarly, treatment of a compound of Formula XVI with an activated ester, lactone or acid chloride yields compounds of Formula XVII in which R7 is acylamino. Treatment of a compound of Formula XVI with a sulfonyl chloride or activated sulfonamide results in Formula XVII in which R7 is a sulfonamino. Treatment of a compound of the Formula XVI with an activated heterocycle results in a compound of Formula XVII in which R7 is a heterocyclic amino. Treatment of a compound of the Formula XVI with an activated heteroaryl results in a compound of Formula XVII in which R7 is a heteroaryl amino. Treatment of a compound of Formula XVI with a carbonate, chloroformate, or cyanoformate gives compounds of Formula XVII in which R7 is a carbamate. Treatment of a compound of Formula XVI with a thioester gives compounds of Formula XVII in which R7 is thioacylamino. Treatment of a compound of Formula XVI with a phosphoryl chloride or phosphoramidate, gives compounds of Formula XVII in which R7 is phosphonamino. Treatment of a compound of Formula XVI with an imidate gives compounds of Formula XVII in which R7 is iminoamino. Treatment of a compound of Formula XVI with a thioisocyanate gives compounds of Formula XVII in which R7 is thioureido. Treatment of a compound of Formula XVI with an an aldehyde or ketone under reductive conditions gives compounds of Formula XVII in which R7 is a monosubstituted amino or a disubstituted amino group. Treatment of a compound of Formula XVI with an imidate gives compounds of Formula XVII in which R7 is iminoamino. Treatment of a compound of Formula XVI with an guanidinylating agent such as
    Figure US20060194714A1-20060831-C00106
    provides compounds of Formula XVII in which R7 is guanidino.
  • It will be understood by those skilled in the art that if a modifying agent contains substituents that are incompatible with the reaction conditions under which the compound of Formula XVII is formed, said substituents will have to be protected prior to use in the reaction. Suitable protecting groups and methods of making them can be found in Greene (vide supra).
  • The reaction of amines of complex molecules such as daptomycin and related depsipeptides can be found in U.S. Pat. Nos. 4,399,067; 4,482,487; and 4,537,717; 5,039,789; and 5,028,590; and International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271.
  • In a preferred embodiment of the reaction the modifying agent is an activated ester. In a more preferred embodiment of the reaction the modifying agent is
    Figure US20060194714A1-20060831-C00107
    wherein each of Raa1, Raa2, and Raa3 is an amino acid side chain or a protected form of an amino acid side chain; R36 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; and X is an activating group. In an even more preferred embodiment, X is an aryloxy group. In a still more preferred embodiment, X is pentafluorophenoxy.
  • Compounds of Formulas XXI, XXII and XXIII can be prepared from the corresponding peptide or amino acid upon treatment with an activating agent such as anhydrides, chloroformates, pentafluorophenol/dicyclohexylcarbodiimide, N′,N′-carbonyldiimidazole, hydroxybenzotriazole or N-hydroxysuccinimide. The peptides can be prepared by any standard peptide procedure. For an overview of some standard peptide formation procedures see Vogel's Textbook of Practical Organic Chemistry, 5th Ed., eds. B. S. Furniss, A. J. Hannaford; P. W. G. Smith; A. R. Tatchell (New York: John Wiley and Sons, Inc.), 1989, pp750-763 and Introduction to Organic Chemistry, 2nd Ed. by A. Streitwieser, Jr. and C. H. Heathcock (New York: MacMillan Publishing Co., Inc.), pp 954-962. Other methods that are useful for the preparation of peptides of the present invention involve synthesis on a solid support. Specific examples of such procedures are detailed in the examples (vide infra).
  • Removal of the protecting group(s) from the protected Formula I compound (the compound of Formula XVII) results in the formation of the compound of Formula Ia (step (h)) wherein, R1, R4, R5, R6, and R7 are as previously described; R2a is methyl or —CH2CH2CH2NH2, and R3a is a methyl or —CH2CH2CH2CH2NH2. Removal of the amino protecting group can be accomplished according to procedures described in Greene (vide supra). As those skilled in the art will recognize, the choice of amino protecting group employed in the first step of the process will dictate the reagents and procedures used in removing said amino protecting group.
  • When the modifying agent contains one or more protecting group(s), said protecting group(s) must also be removed. The choice of the protecting group(s) utilized on the modifying agent substituent(s) will dictate the reagents and procedures used in removing said protecting group(s). When the protecting group(s) utilized on the modifying agent substituent(s) and the protecting group utilized in step (b) are compatable, the protecting groups may be removed in a single step. However, when the protecting group(s) are incompatable multiple steps may be required to remove all of the protecting groups.
  • Process for the Preparation of Compounds of Formula I Wherein at Least One of R2 and R3 is Other than Methyl and Each of R8 and R9 is Other than NH2.
  • Procedure B
  • For compounds of Formula I wherein at least one of R2 and R3 is other than methyl and each of R8 and R9 is other than NH2, the process, in accordance with another aspect of the invention, comprises the additional steps of:
      • (i) treating the Formula I free amine compound of step (h) of Procedure A with a modifying agent to obtain a compound of Formula I.
  • Treatment of the Formula I free amine compound of Formula Ia with a modifying agent are well know to those skilled in the art and are described for step (g) of Procedure A (vide supra).
  • The reaction of free amines of complex molecules such as daptomycin and related depsipeptides can be found in U.S. Pat. Nos. 4,399,067; 4,482,487; and 4,537,717; and International Patent Application Serial Numbers WO01/44272, WO01/44274, and WO01/44271.
  • It will be understood by those skilled in the art that if R7 or the modifying agent of step (i) contain substituents that are incompatible with the reaction conditions under which the compound of Formula I is formed, said substituents will have to be protected prior to step (i). Suitable protecting groups and methods of making them can be found in Greene (vide supra).
  • When R7, and the modifying agent of step (i) contain protecting group(s), said protecting group(s) may be removed. The choice of the protecting group(s) utilized on R7 and the modifying agent substituent(s) will dictate the reagents and procedures used in removing said protecting group(s). When the protecting group(s) utilized on R7, and the modifying agent substituent(s) are compatable, the protecting groups may be removed in a single step. However, when the protecting group(s) are incompatable multiple steps may be required to remove all of the protecting groups.
  • Procedure C
  • An alternate procedure for preparing compounds of Formula I wherein at least one of R2 and R3 is other than methyl and each of R8 and R9 is other than NH2, comprises the steps of:
      • (a) providing a depsipeptide derivative of the Formula XI
        Figure US20060194714A1-20060831-C00108
        • wherein: R, R1, R4, R5, R6, R18, R19, R20, R25, R26 and R27 are as previously described;
      • (b) treating the free amino group(s) of the compound of Formula XI with a modifying agent to obtain a blocked depsipeptide compound wherein said modifying agent is selected such that the blocked depsipeptide compound formed is stable to step (c), (d), (e) (f) and (g);
      • (c) treating the blocked depsipeptide compound obtained in (b) with a deacylating agent to obtain a terminal amino compound;
      • (d) removing the tryptophan amino acid residue of the terminal amino compound obtained in (c) to obtain a destryptophan compound;
      • (e) removing the terminal amino acid residue of the destryptophan compound obtained in (d) to obtain a desdipeptide compound;
      • (f) removing the terminal amino acid residue of the desdipeptide compound obtained in (e) to obtain a depsipeptide core compound;
      • (g) treating the depsipeptide core compound of (f) with a modifying agent.
        Procedure C is described in Scheme V
        Figure US20060194714A1-20060831-C00109
        Figure US20060194714A1-20060831-C00110
        Figure US20060194714A1-20060831-C00111
  • Treatment of the compound of Formula XII with a modifying agent results in the formation of blocked Formula I compound (the compound of Formula XXIV, step (b)) wherein R37 is methyl or —CH2CH2CH2R8; and R38 is methyl or —CH2CH2CH2CH2R9; provided that at least one of R37 and R38 must be other than methyl and R8 and R9 must be other than amino. The formation of the blocked Formula I compound is performed as previously described in step (g) of Procedure A (vide supra)
  • The deacylation of compound XXIV lead to the formation of the terminal amino compound XXV. Suitable agents for the deacylation of compounds of Formula XXIV are enzymatic deacylated agents (vide supra).
  • Removal of the tryptophan amino acid residue from the terminal amino compound of Formula XXV leads to the formation of the compound of Formula XXVI (step (d)). Methods for removal of the tryptophan amino acid residue are known to those skilled in the art. A preferred method for removal of the tryptophan amino acid residue is under Edman degradation conditions (vide supra).
  • Removal of the terminal amino acid residue from the compound of Formula XXVI leads to the formation of the desdipeptide compound of Formula XXVII (step (e)). Methods for removal of the terminal amino acid residue are known to those skilled in the art. A preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • Removal of the terminal amino acid residue from the compound of Formula XXVII leads to the formation of the depsipeptide core compound of Formula XXVIII (step (f)). Methods for removal of the terminal amino acid residue are known to those skilled in the art. A preferred method for removal of the terminal amino acid residue is under Edman degradation conditions (vide supra).
  • Treatment of the depsipeptide compound of Formula XXVIII with a modifying agent are well know to those skilled in the art and are described for step (g) of Procedure A (vide supra).
  • It will be understood by those skilled in the art that if the modifying agent, contain substituents that are incompatible with the reaction conditions under which the compound of Formula I is formed, said substituents must be protected prior to reaction with the compound of Formula XXVIII. Suitable protecting groups and methods of making them can be found in Greene (vide supra).
  • When desired, protecting groups may be removed. When the protecting group(s) are compatable, the protecting groups may be removed in a single step. However, when the protecting group(s) are incompatable multiple steps may be required to remove all of the protecting groups.
  • Procedure D
  • Compounds of Formula I and compounds of Formula Ia in which R7 is
    Figure US20060194714A1-20060831-C00112
  • wherein each of R18, R19, and R20 is as previously described and R39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XIII, as described in Scheme VI, or by compound XXV as described in Scheme VII.
    Figure US20060194714A1-20060831-C00113
    Figure US20060194714A1-20060831-C00114
    Procedure E
  • Similarly compounds of Formula I and compounds of Formula Ia in which R7 is
    Figure US20060194714A1-20060831-C00115
  • wherein each of R18, R19, and R20 is as previously described and R39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XIV, as described Scheme VIII, or by compound XXVI as described in Scheme IX.
    Figure US20060194714A1-20060831-C00116
    Figure US20060194714A1-20060831-C00117
    Procedure F
  • Similarly compounds of Formula I and compounds of Formula Ia in which R7 is
    Figure US20060194714A1-20060831-C00118
  • wherein each of R18, and R19 is as previously described and R39 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino; can be prepared from compound XV, as described Scheme X, or by compound XXVII as described in Scheme XI.
    Figure US20060194714A1-20060831-C00119
    Figure US20060194714A1-20060831-C00120
    • 2. Synthetic Process
  • Solid Support Synthesis of Depsipeptide Compounds
  • In an alternative embodiment of the invention, the depsipeptide compounds of Formula I may be synthesized on a solid support (Scheme XII, Scheme XIII and Scheme XV).
    Figure US20060194714A1-20060831-C00121
  • In step 1, an N-protected-β-methyl glutamic acid-O-allyl ester or a protected glutamic acid-O-allyl ester is coupled to a resin to give Compound 101, wherein R6 is as described previously. A resin or solid support, such as, but not limited to, Wang, HMPA, Safety Catch, Rink Acid, 2-chlorotrityl-chloride resin, trityl-chloride resin, 4-methyltrityl-chloride resin, 4-methoxytrityl-chloride resin or PAM resin may be used in this reaction.
  • Deprotection of Compound 101, followed by coupling of the free amino with a protected serine or protected asparagine affords Compound 102, wherein R40 is —OP2, or —CONHP3; and each of P, P1, P2 and P3 is independently a protecting group. This peptide coupling process, i.e., deprotection of the alpha-amino group, followed by coupling to a protected amino acid, is repeated until the desired number of amino acids has been coupled to the resin. In Scheme XII, a total of seven amino acids have been coupled to give compound 103 wherein, A3 is
    Figure US20060194714A1-20060831-C00122
    A4 is
    Figure US20060194714A1-20060831-C00123
    wherein P4 is a protecting group and R4 is as previously described; A5 is
    Figure US20060194714A1-20060831-C00124
    wherein R44 is methyl or —CH2CH2CH2CH2NP5, wherein P5 is an amino protecting group; A6 is
    Figure US20060194714A1-20060831-C00125
    wherein P6 is a protecting group; and A7 is
    Figure US20060194714A1-20060831-C00126
    wherein R45 is methyl or —CH2CH2CH2NP7, wherein P7 is an amino protecting group. A second peptide is coupled to a resin in a similar fashion, as outlined in Scheme XIII.
    Figure US20060194714A1-20060831-C00127
  • In step 1, a N-protected-glycine or a sarcosine is coupled to a resin to give Compound 104 wherein R1 is as described previously and P8 is an amino protecting group. The choice of resin used in step 1 is dependent upon the nature of the amino acid that is coupled in steps 2-6. If the amino acid side chains contain protecting groups, a resin must be chosen such that the protecting groups remain intact when the resin is removed from the peptide in step 7. Resins that can be cleaved while preserving the protecting groups of peptides include, but are not limited to, Safety Catch, Rink Acid, 2-chlorotrityl-chloride resin, trityl-chloride resin, 4-methyltrityl-chloride resin, 4-methoxytrityl-chloride resin or PAM resin.
  • Deprotection of the protected amino of Compound 104, followed by coupling of the free amino with
    Figure US20060194714A1-20060831-C00128
    affords Compound 105, wherein R41 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
  • When R41 is amino, this peptide coupling process, i.e., deprotection of the alpha-amino group, followed by coupling to a protected amino acid, is repeated until the desired number of amino acids has been coupled to the resin. In Scheme XIII, five amino acids have been coupled to give Compound 108 wherein, A8 is
    Figure US20060194714A1-20060831-C00129
    wherein R46 is hydrido, an amino acid side chain or a protected amino acid side chain; A9 is
    Figure US20060194714A1-20060831-C00130
    wherein R47 is hydrido, an amino acid side chain or
    a protected amino acid side chain; A10 is
    Figure US20060194714A1-20060831-C00131
    wherein R48 is hydrido, an amino acid side chain or a protected amino acid side chain and R49 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino. Compound 108 is coupled with
    Figure US20060194714A1-20060831-C00132
    to give compound 111, wherein P9 is a protecting group and R42 is 2-butyl, isopropyl or
    Figure US20060194714A1-20060831-C00133
  • wherein R43 is a group capable of being converted to an amino group. For example, R43 may be azido, a protected amino phthalimido or nitro.
  • The peptide 111 is then removed from the resin to give compound 112.
  • Coupling of the peptide fragments 103 and 112 is outlined in Scheme XIV
    Figure US20060194714A1-20060831-C00134
  • The peptide fragments 103 and 112 are coupled to yield the resin bound peptide 113. Deprotection of the P9 protecting group and O-allyl ester, followed by cyclization affords a resin-bound depsipeptide 114. Cleavage of the depsipeptide from the resin followed by deprotection of any remaining protecting groups yields compounds of Formula I (Scheme XVI).
  • When compounds of Formula I are desired in which there are no exocyclic amino acids, compound 105 can be used in place of compound 108 (Scheme XV). Compound 105 is coupled with Compound 110 to give Compound 115; removed from the resin to give Compound 116; coupled with Compound 103 to give Compound 117; then deprotected and cyclized to yield a resin bound depsipeptide (118) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
    Figure US20060194714A1-20060831-C00135
  • When compounds of Formula I are desired in which there is one exocyclic amino acids, compound 106 can be used in place of compound 108 (Scheme XVII). Compound 106 is coupled with Compound 110 to give Compound 119; removed from the resin to give Compound 120; coupled with Compound 103 to give Compound 121; then deprotected and cyclized to yield a resin bound depsipeptide (122) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
    Figure US20060194714A1-20060831-C00136
  • When compounds of Formula I are desired in which there are two exocyclic amino acids, compound 107 can be used in place of compound 108 (Scheme XVIII). Compound 106 is coupled with Compound 110 to give Compound 123; removed from the resin to give Compound 124; coupled with Compound 103 to give Compound 125; then deprotected and cyclized to yield a resin bound depsipeptide (126) and cleaved from the resin as described previously in Schemes XIII and XIV (vide supra).
    Figure US20060194714A1-20060831-C00137
  • Following the synthetic schemes above (Schemes XII-XVII), it is understood that both the amino acid amino group and the amino acid side chain functional groups must be orthogonally protected prior to attaching them to the growing peptide chain. Suitable protecting groups can be any amino protecting group useful in peptide synthesis. Such pairings of protecting groups are well known. See, e.g., “Synthesis Notes” in the Novabiochem Catalog and Peptide Synthesis Handbook (1999), pages S1-S93 and references cited therein.
  • It will also be understood by those skilled in the art that the choice of protecting group on the amino acid side chain functional groups will either result or not result in the protecting group being cleaved concomitantly with the peptide's final cleavage from the resin, which will give the natural amino acid functionality or a protected derivative thereof, respectively. When the protecting groups are not concomitantly cleaved when the depsipeptide is cleaved from the resin, additional deprotection may be necessary
    • 3. Biosynthetic Process
  • The compounds of the present invention can also be prepared by recombinant methods. In this process a modified non-ribosomal peptide synthetase of daptomycin is introduced into a cell capable of producing a compound of Formula I an d the cell is cultured to form a compound of Formula I. The non-ribosomal peptide synthetases of daptomycin as well as modifications of these synthetases have been reported (see International Patent Application Serial Number 02/059,322).
  • In order that this invention may be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
    • EXAMPLE 1 Synthesis of Peptide Resin Compound 1
  • Figure US20060194714A1-20060831-C00138
  • The commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-threonine (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to commercially available glycine 2-chlorotrityl resin (334 mg). The mixture was shaken for one hour, filtered and a few beads were tested for the presence of a free amine using the standard Kaiser test (see E. Kaiser, et al (1970) Anal. Biochem., 34, 595; and Advanced Chemtech Handbook of Combinatorial, Organic and Peptide Chemistry 2003-2004 page 208). The Kaiser test gave a blue color so the coupling conditions above were repeated. After filtration the product bearing resin was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 2.
    Figure US20060194714A1-20060831-C00139
  • Compound 2 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 3.
    Figure US20060194714A1-20060831-C00140
  • The commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid β-tert-butyl ester (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to compound 3. The mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound.
    Figure US20060194714A1-20060831-C00141
  • Compound 4 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 5.
    Figure US20060194714A1-20060831-C00142
  • The commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-asparagine δ-N-trityl (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 5. The reaction mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 6.
    Figure US20060194714A1-20060831-C00143
  • Compound 6 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 7.
    Figure US20060194714A1-20060831-C00144
  • The commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-tryptophan (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin. The reaction mixture was shaken for one hour, then filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 8.
    Figure US20060194714A1-20060831-C00145
  • Compound 8 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give resin peptide compound
    • EXAMPLE 2 Synthesis of Peptide Resin Compound 9
  • Figure US20060194714A1-20060831-C00146
  • To a suspension of commercially available 4-hydroxymethylphenoxy resin (Wang resin) (5 g, 0.4 mmol/g) in dichloromethane (60 mL) was added 1,3-diisopropylcarbodiimide (0.940 mL), 4-dimethylaminopyridine (24 mg in N-methylpyrolidine (1 mL)), and commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-glutamic acid α-allyl ester (2.46 g in N-methylpyrolidine (9 mL)). The reaction mixture was stirred for 16 hours, filtered, and the solid was washed with N-methylpyrolidine and dichloromethane and dried to give compound 10.
    Figure US20060194714A1-20060831-C00147
  • Compound 10 (526 mg) was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 11.
    Figure US20060194714A1-20060831-C00148
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-serine-tert-butyl ether (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 11. The reaction mixture was shaken for one hour, then filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 12.
    Figure US20060194714A1-20060831-C00149
  • Compound 12 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 13.
    Figure US20060194714A1-20060831-C00150
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-glycine ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 13. The reaction mixture was shaken for one hour, then filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 14.
    Figure US20060194714A1-20060831-C00151
  • Compound 14 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 15.
    Figure US20060194714A1-20060831-C00152
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid β-tert-butyl ester ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) were added to resin 15. The reaction mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 16.
    Figure US20060194714A1-20060831-C00153
  • Compound 16 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 17.
    Figure US20060194714A1-20060831-C00154
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-alanine ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 17. The reaction mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 18.
    Figure US20060194714A1-20060831-C00155
  • Compound 18 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 19.
    Figure US20060194714A1-20060831-C00156
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-aspartic acid β-tertbutyl ester ((2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 19. The reaction mixture was shaken for one hour, filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 20.
    Figure US20060194714A1-20060831-C00157
  • Compound 20 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 21.
    Figure US20060194714A1-20060831-C00158
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-Nδ-(tertbutoxycarbonyl)-L-ornithine (2 mL of a 0.5 molar solution in N-methylpyrolidine), 1,3-diisopropylcarbodiimide (2 mL of a 0.5 molar solution in N-methylpyrolidine), and 1-hydroxy-benzotriazole (2 mL of a 0.5 molar solution in N-methylpyrolidine) was added to resin 21. The reaction mixture was shaken for one hour, then filtered and the coupling was repeated. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 22.
    Figure US20060194714A1-20060831-C00159
  • Compound 22 was agitated in 20% piperidine in N-methylpyrolidine (6 mL) for 30 minutes. The resin was filtered and re-suspended in 20% piperidine in N-methylpyrolidine (6 mL) and agitated for 30 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL) to give compound 9.
    • EXAMPLE 3 Synthesis of Peptide Resin Compound 23
  • Figure US20060194714A1-20060831-C00160
  • Resin peptide 1 (2 g) was added to a solution of the pentafluorophenyl ester of decanoic acid 24 (440 mg, for the preparation of compound 24 see Example 6, Reaction 1) in dichloromethane. The mixture was shaken for 17 hours, filtered, and the reaction was judged to be incomplete using the Kaiser Test (vide supra). Decanoic acid (517 mg), 1-hydroxy-benzotriazole (446 mg), and 1,3-diisopropylcarbodiimide (438 μL) were dissolved in N-methylpyrolidine (8 mL) and stirred for one hour. The resin was then added to the mixture then stirred for 8 hours, filtered and washed with N-methylpyrolidine (3×6 mL), methanol (3×6 mL), and again with N-methylpyrolidine (3×6 mL). The reaction was found to be complete using the Kaiser Test, yielding the resin bound lipopetide 23.
    • EXAMPLE 4 Synthesis of Compound 29
  • Figure US20060194714A1-20060831-C00161
  • L-2-N-(allyloxycarbonyl)-4-(2-azidophenyl)-4-oxobutanoic acid 25 (636 mg, see example 15 (vide infra)), 4-dimethylaminopyridine (25 mg), and N-methyl-2-chloropyridinium iodide (511 mg) were flushed well with argon, then suspended in dichloromethane (10 mL). Triethylamine (560 μL) was added and the reaction mixture was stirred to give a homogeneous solution. Resin lipopeptide 23 (667 mg) was added to the solution and the flask was flushed again with argon and shaken for 17 hours. A 20 mg sample of the resin was removed to test the reaction for completion (20 mgs of resin in dichloromethane (0.6 ml) was treated with 2,2,2-trifluoroethanol, (0.2 ml) and acetic acid (0.2 ml) and stirred for 3 hours. The reaction mixture was filtered, and the solvent was evaporated to give a residue. Liquid Chromatography/Mass Spectral analysis of the residue indicated the reaction was incomplete). Coupling was judged to be incomplete so the resin was dried under reduced pressure for 5 days, and the above coupling was repeated over another 17 hours. The reaction mixture was filtered and the solid was washed well with dichloromethane. The solid was then suspended in dichloromethane (6 mL), 2,2,2-trifluoroethanol (2 mL), acetic acid (2 mL), and shaken for 5 hours. The reaction mixture was filtered and evaporation of the filtrate gave the crude desired peptide 26 (44 mg). The crude product was purified by reverse phase HPLC (C18 10 uM Jupiter column 250×21.2 mm) eluting with a gradient from 20% acetonitrile 0.5% formic acid: 80% water 0.5% formic acid to 80% acetonitrile 0.5% formic acid: 20% water 0.5% formic acid over 25 minutes. The product bearing fractions were freeze-dried to give the pure product 26 (10.6 mg).
    Figure US20060194714A1-20060831-C00162
  • Hydroxy-benzotriazole (5 mgs), 1,3-diisopropylcarbodiimide (6 μL), and peptide resin 9 (12.3 mg) were added to a solution of compound 26 (10.6 mg) in N-methylpyrolidine (0.7 mL) then shaken for 22 hours. The resin was filtered and the coupling was judged to be complete using the Kaiser Test, yielding resin bound lipopeptide 27.
    Figure US20060194714A1-20060831-C00163
  • The dried resin 27 was placed under an argon atmosphere, and treated with a solution of tetrakis-(triphenylphosphine)palladium(0) (19 mg) in dichloromethane (1.47 mL), acetic acid (74 μL), and N-methylmorpholine (37 μL). The mixture was shaken for 4 hours at ambient temperature, filtered, and the solid was washed with two times with N-methylmorpholine, two times with methanol, and again two times with N-methylmorpholine. 1-Hydroxy-benzotriazole (0.5 mL of a 0.5 molar solution in N-methylmorpholine) and 1,3-diisopropylcarbodiimide (0.5 mL of a 0.5 molar solution in N-methylmorpholine) were added to the resin. The reaction was shaken for 17 hours, filtered, and washed well with N-methylmorpholine to give the resin bound cyclized depsipeptide 28.
    Figure US20060194714A1-20060831-C00164
  • The dried resin 28 was suspended in dichloromethane, (4 mL) trifluoroacetic acid, (6 mL) ethanedithiol (250 μl), and triisopropylsilane (250 μl), and the reaction mixture was stirred for 3 hours at ambient temperature. The resin was filtered and the combined filtrates were evaporated under reduced pressure. Crude product was then partitioned between diethyl ether (6 mL), and water (3 mL). The aqueous layer was freeze-dried to give crude product. The crude product was purified by reverse phase HPLC (C18 10 uM Jupiter column 250×21.2 mm) eluting with a gradient from 20% acetonitrile 0.5% formic acid: 80% water 0.5% formic acid to 80% acetonitrile 0.5% formic acid: 20% water 0.5% formic acid over 25 minutes. The product bearing fractions were combined and freeze-dried to give the pure product 29 (1.0 mg).
    • EXAMPLE 5 Synthesis of Compound 33
  • Figure US20060194714A1-20060831-C00165
  • Commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-isoleucine (95 mg), 4-dimethylaminopyridine (6 mg), and N-methyl-2-chloropyridinium iodide (69 mg) were flushed well with argon then suspended in dichloromethane (2.7 mL). Triethylamine (76 μL) was added and the reaction mixture was stirred to give a homogeneous solution. Resin lipopeptide 23 (200 mg) was added to the solution, the flask was flushed again with argon and then shaken for 14 hours. The resulting resin was then filtered and washed well with dichloromethane. The solid was suspended in dichloromethane (6 mL), 2,2,2-trifluoroethanol (2 mL), and acetic acid (2 mL), and shaken for 3 hours. The resin was filtered and evaporation of the filtrate gave the desired peptide 30 (54 mg) as a white solid.
    Figure US20060194714A1-20060831-C00166
  • 1-Hydroxy-benzotriazole (26 mg), 1,3-diisopropylcarbodiimide (30 μl), and peptide resin 9 (64 mg) were added to a solution of the depsipeptide 30 (54 mg) in N-methylmorpholine (3.8 mL), and the resulting mixture was shaken for 22 hours. The resin was filtered, and the coupling was judged to be complete using the Kaiser Test, yielding the resin bound depsipeptide 31.
    Figure US20060194714A1-20060831-C00167
  • The dried resin 31 was placed under an argon atmosphere, and treated with a solution of tetrakis-(triphenylphosphine)palladium(0) (48 mg in dichloromethane (7.63 mL)), acetic acid (0.38 mL), and N-methylmorpholine (0.19 mL). The mixture was shaken for 4 hours at ambient temperature, filtered, and the solid was washed two times with N-methylmorpholine, two times with methanol, and again two times with N-methylmorpholine. The solid resin was suspended in 20% piperidine in N-methylmorpholine (7 mL) for 105 minutes, filtered and the solid was washed well with N-methylmorpholine. 1-Hydroxy-benzotriazole (0.3 mL of a 0.5 molar solution in N-methylmorpholine) and 1,3-diisopropylcarbodiimide (0.3 mL of a 0.5 molar solution in N-methylmorpholine) were added to the resin. The reaction was shaken for 17 hours, filtered, and the precipiate was washed well with N-methylmorpholine to give the resin bound cyclized depsipeptide 32.
    Figure US20060194714A1-20060831-C00168
  • The dried resin 32 was suspended in dichloromethane (4 mL), trifluoroacetic acid (6 mL), ethanedithiol (250 μl), and triisopropylsilane (250 μl), and stirred for 3 hours at ambient temperature. The reaction mixture was filtered an washed with dichloromethane (2×2 mL) and the combined filtrates were evaporated under reduced pressure. Crude product was then partitioned between diethyl ether (6 mL) and water (3 mL). The aqueous layer was separated and freeze dried to give the crude product 33 (21.5 mgs). The crude product was then purified by reverse phase HPLC (C18 10 uM Jupiter column 250×21.2 mm) eluting with a gradient from 20% acetonitrile 0.5% formic acid: 80% water 0.5% formic acid to 80% acetonitrile 0.5% formic acid: 20% water 0.5% formic acid over 25 minutes. The product bearing fractions were combined and freeze-dried to give the pure product 33 (1.8 mg).
    • EXAMPLE 6 Synthesis of Compound 34
  • Figure US20060194714A1-20060831-C00169
  • To a solution of commercially available decanoic acid (13.78 g) in tetrahydrofuran (40 mL), was added 1,3-diisopropylcarbodiimide (13.76 mL). After 5 minutes a solution of pentafluorophenol (16.20 g) in tetrahydrofuran (40 mL) was added and the reaction mixture was stirred for 72 hours. The resulting mixture was filtered; the residue was washed with tetrahydrofuran (40 mL) and the tetrahydrofuran filtrates were combined. The solvent was evaporated and the residue was purified on silica gel using 9:1 hexane:ethyl acetate as an eluent to give the desired product 24 as an oil (23.49 g)
    Figure US20060194714A1-20060831-C00170
  • A solution of commercially available Boc-L-3-Benzothienylalanine 35 (1.0 g) in dry methanol (20 mL) was cooled to 0° C. in an ice bath. Thionyl chloride (1.63 mL) was added dropwise, and the reaction mixture was allowed to warm to ambient temperature over 16 hours. Evaporation of the solvent gave a crude product that was partitioned between ethyl acetate and aqueous potassium bicarbonate. The organic layer was washed with aqueous potassium bicarbonate, and saturated sodium chloride, dried with anhydrous sodium sulphate and evaporated to give the product 36 (0.66 g).
    Figure US20060194714A1-20060831-C00171
  • To a solution of the Benzothienylalanine-methyl ester 36 (0.66 g) in tetrahydrofuran (10 mL) was added a solution of the decanoyl pentafluorophenolester 24 (1.04 g) in tetrahydrofuran (10 mL). The resulting solution was stirred for 24 hours. The reaction mixture was poured into ethyl acetate and washed successively with 1 N hydrochloric acid, 10% aqueous potassium carbonate, and saturated sodium chloride. The combined organic layer was then dried with anhydrous sodium sulphate and evaporated to give product 37 (1.40 g) which was used as crude material in the next reaction
    Figure US20060194714A1-20060831-C00172
  • Lithium hydroxide mono hydrate (0.59 g) was added to a solution of compound 37 (1.40 g) methanol (15 mL) and water (3 mL) and the reaction mixture was stirred for one hour. The methanol was removed by evaporation and the aqueous solution was acidified to pH 1 with 1 N hydrochloric acid and extracted with ethyl acetate. The organic layers were combined and dried with anhydrous sodium sulphate and evaporated to give the product 38.
    Figure US20060194714A1-20060831-C00173
  • 1,3-Diisopropylcarbodiimide (121 mg) was added to a solution of the compound 38 (200 mg), and pentafluorophenol (108 mg) in tetrahydrofuran (5 mL) and the reaction mixture was stirred for one hour. The resulting mixture was filtered, the solvent was evaporated and the residue was purified on silica gel. Using 9:1 hexane:ethyl acetate as an eluent gave the faster running impurity and 4:1 hexane:ethyl acetate as an eluent gave the product 34 (80 mg).
    • EXAMPLE 7 Synthesis of Compound 39
  • Figure US20060194714A1-20060831-C00174
  • Compound 39 was prepared from commercially available 40 via the conditions described above as follows: Compound 39 was converted to the corresponding methyl ester under the conditions described in Example 6, Reaction 2. The methyl ester was acylated under the conditions described in Example 6, Reaction 3. The acylated compound was then saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 39 via the conditions described in Example 6, Reaction 5.
    • EXAMPLE 8 Synthesis of Compound 41
  • Figure US20060194714A1-20060831-C00175
  • Commercially available compound 42 was converted to compound 43 under the conditions described in Example 6, Reaction 2
    Figure US20060194714A1-20060831-C00176
  • Decanoyl chloride (0.51 mL) was added to a solution of amino acid methyl ester 43(440 mg) and triethylamine (0.43 mL) cooled to 0° C. in an ice bath. The reaction was allowed to warm to ambient temperature over three hours. The reaction was then poured into ethyl acetate and washed successively with water, and saturated sodium chloride. The organic layers were then dried with anhydrous sodium sulphate and evaporated to give the product 44.
    Figure US20060194714A1-20060831-C00177
  • Compound 44 was converted to compound 41 via the conditions described in the as follows. Compound 44 was saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 41 via the conditions described in Example 6, Reaction 5.
    Figure US20060194714A1-20060831-C00178
  • Compound 45 was prepared from commercially available 46 via the conditions described above as follows: Compound 46 was converted to the corresponding methyl ester under the conditions described in Example 6, Reaction 2. The methyl ester was acylated under the conditions described in Example 8, Reaction 2. The acylated compound was then saponified under the reaction conditions described in Example 6, Reaction 4. The saponified material was then converted to compound 45 via the conditions described in Example 6, Reaction 5.
    • EXAMPLE 10 Synthesis of Compound 47
  • Figure US20060194714A1-20060831-C00179
  • Commercially available 48 was treated under the conditions described in Example 6, Reaction 3 above to afford compound 49. Treatment of compound 49 as described in Example 6, Reaction 5 gave compound 47.
    • EXAMPLE 11 Synthesis of Compound 50
  • Figure US20060194714A1-20060831-C00180
  • Commercially available 51 was treated under the conditions described in Example 6, Reaction 3 above, with the single modification being the use of N,N′-dimethylformamide solvent in place of tetrahydrofuran solvent, to afford compound 52. Treatment of compound 52 as described in Example 6, Reaction 5 above, with the single modification being the use of N,N′-dimethylformamide solvent in place of tetrahydrofuran solvent, gave compound 50.
    • EXAMPLE 12 Synthesis of Compound 53
  • Figure US20060194714A1-20060831-C00181
  • A solution of commercially available ethyl indole-2-carboxylate 54 (2 g), iododecane (2.25 mL), and potassium carbonate (2.92 g) in dry dimethylformamide (30 mL) was stirred for 24 hours. The reaction was poured into ethyl acetate (200 mL) and washed with water (300 mL). The organic layer was then dried with anhydrous magnesium sulphate and evaporated to give the product 55 (2.604 g).
    Figure US20060194714A1-20060831-C00182
  • Lithium hydroxide/water (1.65 g) in water (16 mL) was added to a solution of compound 55 (2.6 g) in tetrahydrofuran (16 mL) and stirred for 4 days. Ethyl acetate (20 mL) and water (10 mL) were added and the aqueous layer was adjusted to pH 1 and extracted with ethyl acetate (3×5 mL). The organic layers were combined, dried and evaporated to give an oil. The hydrolysis was incomplete so the oil was dissolved in methanol/water 2:1 and potassium hydroxide (0.88 g) was added. The reaction mixture was stirred for 15 hours. Ethyl acetate (20 mL) and water (10 mL) were added the layers were separated, and the aqueous layer was adjusted to pH 1 and extracted with ethyl acetate (3×5 mL). The organic layers were combined, dried and evaporated to give the crude product as an oil which was purified on silica gel using 10:1 hexane:ethyl acetate as an eluent to give the product 56 (0.35 g).
    Figure US20060194714A1-20060831-C00183
  • 1,3-Diisopropylcarbodiimide (206 mg) was added to a solution of the compound 56 (340 mg), and pentafluorophenol (227 mg) in dichloromethane (5 mL) and the reaction mixture was stirred for 15 hours. The mixture was quenched with hexane, filtered, and the solvent was evaporated. Purification of the residue on silica gel with 20:1 hexane:ethyl acetate gave the product 53 (490 mg).
    • EXAMPLE 13 Synthesis of Compound 57
  • Figure US20060194714A1-20060831-C00184
  • To a solution of commercially available tryptophan methyl ester 58 (2.54 g) and triethylamine (2.9 mL) in dichloromethane (10 mL) was added 4-dimethylaminopyridine (0.12 g) and acetic anhydride (1.03 mL). After 18 hours the reaction mixture was quenched with 1N hydrochloric acid (10 mL), and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with saturated sodium bicarbonate and saturated sodium chloride then dried with anhydrous sodium sulphate and evaporated to a crude product. Purification on silica gel with 2:1 hexane:ethyl acetate gave the product 59 (1.99 g).
    Figure US20060194714A1-20060831-C00185
  • Compound 59 was alkylated under the conditions described in Example 8, Reaction 2 above, substituting potassium hydroxide for potassium carbonate, to afford compound 60.
    Figure US20060194714A1-20060831-C00186
  • Hydrolysis of compound 60 utilizing the procedure described in Example 6, Reaction 4 gave compound 61.
    Figure US20060194714A1-20060831-C00187
  • Compound 61 was converted to compound 57 utilizing the conditions described in Example 6, Reaction 4.
    • EXAMPLE 14 Synthesis of Compound 62
  • Figure US20060194714A1-20060831-C00188
  • Commercially available tryptophan methyl ester 58 is converted to Compound 63 via the conditions described in Example 8, Reaction 2.
    Figure US20060194714A1-20060831-C00189
  • Compound 63 is then converted to Compound 64 utilizing the conditions described in Example 12, Reaction 1 using methyl iodide in place of iododecane.
    Figure US20060194714A1-20060831-C00190
  • Compound 64 was hydrolyzed using the conditions described in Example 13, Reaction 3 to afford Compound 65.
    Figure US20060194714A1-20060831-C00191
  • Compound 65 was converted to Compound 62 utilizing the conditions described in Example 13, Reaction 4.
    • EXAMPLE 15 Synthesis of Compound 25
  • Figure US20060194714A1-20060831-C00192
  • To a suspension of the commercially available L-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid A (3.93 g) and triethylamine (5.79 mL) in tetrahydrofuran (181 mL), was added sufficient water to obtain a homogenous solution. The solution was then cooled to 0° C. in an ice bath, and diallyl pyrocarbonate (3.36 mL) was added dropwise. The reaction mixture was allowed to warm to ambient temperature over 16 hours, then was concentrated to one third the original volume. The mixture was poured into dichloromethane (350 mL), washed with 1N hydrochloric acid (3×100 mL) and saturated sodium chloride (1×100 mL). The combined aqueous layers were back extracted with ethyl acetate (4×100 mL), and the combined organic fraction was dried with anhydrous sodium sulphate. Evaporation of the solvent gave product B as a yellow solid (5.14 g)
    Figure US20060194714A1-20060831-C00193
  • To a −2° C. solution of compound B (5.00 g) in water (130 mL) and concentrated hydrochloric acid (43 mL), was added a solution of sodium nitrite (1.30 g) in water (3 mL) via dropwise addition, so that the temperature remained below 0° C. The reaction mixture was stirred at −4° C. for 135 minutes and a solution of sodium azide (3.34 g) in water (3 mL) was added. The reaction mixture was allowed to warm to ambient temperature over 16 hours. The mixture was then poured into water (130 mL), and the aqueous phase was extracted with dichloromethane (4×80 mL). The combined organic layer was then dried with anhydrous sodium sulphate. Evaporation of the solvent gave the product 25 as an orange foam (5.14 g)
    • EXAMPLE 16 Synthesis of Compound 77
  • Figure US20060194714A1-20060831-C00194
  • To a suspension of commercially available 2-chlorotritylresin C (1 g), and commercially available 2-N-(9-Fluorenylmethoxycarbonyl)-4-N(tert-butoxycarbonyl)-L-2,4-diaminobutyric acid in dichloromethane D (10 mL), was added diisopropylethylamine (1.65 mL). The mixture was shaken for 3 hours, filtered, and the solid was washed with dichloromethane (10 mL), then dried to give E.
    Figure US20060194714A1-20060831-C00195
  • Compound E was agitated in 20% piperidine in N-methylpyrolidine (20 mL) for 60 minutes. The reaction mixture was filtered then the solid washed with N-methylpyrolidine (20 mL) to give compound F.
    Figure US20060194714A1-20060831-C00196
  • Diisopropylethylamine (0.5 mL) was added to a solution of commercially available Nα-(9-Fluorenylmethoxycarbonyl)-L-tryptophan (1.23 g), TBTU (0.92 g) and N,N-dimethylformamide (10 mL) and the resulting mixture was shaken for 10 minutes. The solution was then added to resin F, shaken for one hour, filtered, and the solid was washed with N-methylpyrolidine (10 mL) to give compound G.
    Figure US20060194714A1-20060831-C00197
  • Compound G was agitated in 20% piperidine in N-methylpyrolidine (20 mL) for 60 minutes. The reaction mixture was filtered then the solid was washed with N-methylpyrolidine (20 mL) to give compound H.
    Figure US20060194714A1-20060831-C00198
  • Diisopropylethylamine (0.5 mL) was added to a solution of commercially available decanoic acid (0.50 g), TBTU (0.92 g) and N,N-dimethylformamide (15 mL) and the resulting mixture was shaken for 10 minutes. The solution was then added to the resin H, shaken for one hour, filtered, and the solid was washed with N-methylpyrolidine (10 mL) to give compound I.
    Figure US20060194714A1-20060831-C00199
  • Compound I was treated with dichloromethane:2,2,2,-trifluoroethanol:acetic acid (3:1:1) and the resulting mixture was shaken for 3 hours. The reaction mixture was then filtered and the filtrate was evaporated to give compound J as a white solid (180 mg).
    Figure US20060194714A1-20060831-C00200
  • Compound J was converted to compound 77 utilizing the conditions described in Example 6, Reaction 4.
    • EXAMPLE 17 Synthesis of Alloc Protected Daptomycin: Compound 67
  • Figure US20060194714A1-20060831-C00201
  • To a solution of daptomycin 66 (10 g) in dry N,N′-dimethylformamide (40 mL) at 0° C. was added allyl-1-benzotriazolylcarbonate (13.5 g). The reaction mixture was allowed to warm up to room temperature and stirred for 18 hours. The mixture was diluted with water (200 mL) then loaded on Bondesil 40 μM C8 resin (400 g) that had been prewashed with methanol (1 L) and water (1 L). The resin was washed with water (1 L) and the product was eluted with methanol (1 L). Evaporation of the methanol gave compound 67 as a yellow solid (1 g).
    • EXAMPLE 18 Preparation of Compound 68
  • Figure US20060194714A1-20060831-C00202
  • A preparation of deacylase enzyme was produced from recombinant Streptomyces lividans, which expresses the Actinoplanes utahensis deacylase enzyme. The enzyme in aqueous ethylene glycol (10 mL) was added to a solution of compound 67 (15 g in water; 1.9 L) at pH 8. The reaction mixture was stirred at room temperature for 18 hours and the pH was adjusted to 8 using 1 M sodium hydroxide. The reaction mixture was poured on to Bondesil 40 μM C8 resin (400 g) that had been prewashed with methanol (1 L) and water (1 L). The product was eluted with 20% acetonitrile in water (1 L) and freeze-dried to give compound 68 as a yellow solid (9.1 g).
    • EXAMPLE 19 Edman Degradation to Remove Tryptophan Preparation of Compound 70
  • Figure US20060194714A1-20060831-C00203
  • To a suspension of compound 68 (9.1 g) in dry N,N′-dimethylformamide (15 mL) was added n-decylisothiocyanate (1.2 mL). The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was poured on to Bondesil 40 μM C8 resin (400 g) that had been pre-washed with methanol (1 L) and water (1 L). The product was eluted with methanol (800 mL) after being first washed with water (800 mL) followed by 20% acetonitrile in water (800 mL). Evaporation of the methanol gave compound 69 as a yellow solid (7.3 g).
    Figure US20060194714A1-20060831-C00204
  • Compound 69 (7.3 g) was stirred at room temperature in 25% trifluoroacetic acid in dry dichloromethane (30 mL) for 2 hours before being evaporated to dryness. The residue was dissolved in water (50 mL) poured on to Bondesil 40 μM C8 resin (400 g) that had been pre-washed with methanol (1 L) and water (1 L). The product was eluted with a 20 to 40% acetonitrile in water gradient and freeze-dried to give compound 70 as a yellow solid (1.05 g).
    • EXAMPLE 20 Edman Degradation to Remove Asparagine Preparation of Desasparagine Compound 72
  • Figure US20060194714A1-20060831-C00205
  • To a suspension of compound 70 (0.57 g) in dry N,N′-dimethylformamide (5 mL) was added n-decylisothiocyanate (0.16 mL). The reaction mixture was stirred at room temperature for 18 hours before evaporation to dryness. The residue was tritrated with diethylether (5 mL) to give compound 71 as a yellow solid (0.54 g).
    Figure US20060194714A1-20060831-C00206
  • Compound 71 (0.54 g) was stirred in 50% trifluoroacetic acid in dry dichloromethane (4 mL) for 2 hours before evaporation to dryness. The residue was dissolved in water (25 mL) poured on to Bondesil 40 μM C8 resin (50 g) that had been pre-washed with methanol (100 mL) and water (100 mL). The product was eluted with 20% acetonitrile in water after first being washed with water (100 mL). The eluent was evaporated to dryness to give compound 72 as a yellow solid (0.40 g).
    • EXAMPLE 21 Edman Degradation to Remove Aspatic Acid Preparation of Core Compound 74
  • Figure US20060194714A1-20060831-C00207
  • Phenylisothiocyanate (1 mmol) is added to a suspension of compound 72 (1.0 mmol) in dry N,N′-dimethylformamide (5 mL). The reaction is stirred at ambient temperature for 18 hours, then evaporated to dryness. The residue is titurated with diethyl ether (5 mL) to give the product 73.
    Figure US20060194714A1-20060831-C00208
  • Compound 73 is stirred in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) for 2 hours, before being evaporated to dryness to give the product as the triflouroacetic acid salt 74.
    • EXAMPLE 22 Preparation of Compound 76
  • Figure US20060194714A1-20060831-C00209
  • Compound 50 (397 mg) was added to a solution of the deacylated destrptophan daptomycin 70 (500 mg), and diisopropylethylamine (2-3 drops) in N,N′-dimethylformamide (5 mL). The reaction was monitored by analytical reverse phase HPLC (eluting with a gradient from 5% to 95% acetonitrile 0.1% formic acid in water 0.1% formic acid using a luna C18 5 uM 150×3 mm) and complete consumption of compound 70 was observed after stirring for 16 hours. The solvent was removed by evaporation and the crude product 75 (631 mg) was carried forward in the next step.
    Figure US20060194714A1-20060831-C00210
  • Tetrakis-(triphenylphosphine)palladium(0), (631 mg) was added to a solution of Compound 75 (631 mg), N-methyl morpholine (631 μl) in dioxane (10 mL) and 1 N hydrochloric acid (6.31 mL). After stirring for 16 hours the reaction was filtered, and purified by reverse phase HPLC using C18 10 uM Jupiter column 250×21.2 mm, eluting with a gradient from acetonitrile:water:formic acid 30:70:0.1 to acetonitrile:water:formic acid 90:10:0.1 over 25 minutes. Evaporation of the product bearing fractions gave the product 76 (44 mg).
    • EXAMPLE 23 Preparation of Compound 79
  • Figure US20060194714A1-20060831-C00211
  • Compound 77 (1.2 mmol, see example 16 (vide supra)) is added to a solution of the deacylated destryptophan-desasparagine daptomycin 72 (1.0 mmol) and diisopropylethylamine (2-3 drops) in dry dimethylformamide (5 mL). The reaction is stirred at ambient temperature until all the starting material is consumed as determined by analytical reverse phase HPLC (eluting with a gradient from 5% to 95% acetonitrile 0.1% formic acid in water 0.1% formic acid using a luna C18 5 uM 150×3 mm) The mixture is evaporated to dryness and the residue is titurated with ether (5 mL) to give the desired product 78.
    Figure US20060194714A1-20060831-C00212
  • To a solution of compound 78 (1 mmol) in 0.5 M hydrochloric acid (1 mL) and dioxane (3 mL), is added N-methylmorpholine (0.1 mL) and tetrakis-(triphenylphosphine)-palladium(0) (100 mg). The reaction is stirred under argon for 24 hours, filtered and concentrated to give a crude semi solid. The residue is dissolved in dry dichloromethane (4 mL). Triisopropylsilane (0.1 mL) and trifluoroacetic acid (1 mL) are added and the reaction is stirred for 2 hours before being evaporated to dryness. The residue is then purified by preparative HPLC with a 250×21.2 mm Jupiter 10 μm C8 column using a 30-80% acetonitrile gradient in 0.1% aqueous formic acid as eluent. Evaporation of the solvent from the product bearing fractions gives the desired product 79.
    • EXAMPLE 24 Biological Activity
  • Compounds according to Formula I were tested for antimicrobial activity against a panel of organisms according to standard procedures described by the National Committee for Clinical Laboratory Standards (NCCLS document M7-A5, Vol. 20, No. 2, 2000) except that all testing was performed at 37° C. Compounds were dissolved in 100% dimethyl sulfoxide and were diluted to the final reaction concentration (0.1 μg/mL-100 μg/mL) in microbial growth media. In all cases the final concentration of dimethyl sulfoxide incubated with cells is less than or equal to 1%. For minimum inhibitory concentration (MIC) calculations, 2-fold dilutions of compounds were added to wells of a microtiter plate containing 5×104 bacteria cells in a final volume of 100 μL of media (Mueller-Hinton Broth supplemented with 50 mg/L Ca2+). The optical densities (OD) of the bacterial cells, which measures bacterial cell growth and proliferation, were measured using a commercial plate reader. The MIC value is defined as the lowest compound concentration inhibiting growth of the test organism. The MIC (in μg/ml) value of representative compounds of the present invention are listed in Table III.
    TABLE III
    Biological Activity of Compounds of Formula I
    Figure US20060194714A1-20060831-C00213
    Q SA 399 SA 42 Efm 14 Efs 201
    Figure US20060194714A1-20060831-C00214
         		+++ ++ ++ ++
    Figure US20060194714A1-20060831-C00215
         		++ ++ + ++
    Figure US20060194714A1-20060831-C00216
         		++ ++ ++ ++
    Figure US20060194714A1-20060831-C00217
         		++ ++ + +
    Figure US20060194714A1-20060831-C00218
         		++ ++ ++ ++
    Figure US20060194714A1-20060831-C00219
         		+++ +++ ++ ++
    Figure US20060194714A1-20060831-C00220
         		++ + +
    Figure US20060194714A1-20060831-C00221
         		++ ++ + +
    Figure US20060194714A1-20060831-C00222
         		++ ++ ++ ++
    Figure US20060194714A1-20060831-C00223
         		++ ++ + ++
    Figure US20060194714A1-20060831-C00224
         		+++ +++ ++ ++
    Figure US20060194714A1-20060831-C00225
         		+++ +++ ++ ++
    Figure US20060194714A1-20060831-C00226
         		++ + +

    SA399 is Methicillin Resistant Staphylococcus aureus.
    SA42 is Wild Type Staphylococcus aureus.
    EF14 is Wild Type Enterococcus faecium.
    EF201 is Wild Type Enterococcus faecalis.
  • Wherein “+++” indicates that the compound has an MIC (μg/ml) of 1 μg/ml or less or an ED50 of 1 mg/kg or less;
  • “++” indicates that the compound has an MIC (μg/ml) or ED50 of greater than 1 μg/ml or 1 mg/kg, respectively but less than or equal to 10 μg/ml or ED50 of 10 mg/kg, respectively; and
  • “+” indicates that the compound has an MIC (μg/ml) of greater than 10 μg/ml or an ED50 of greater than 10 mg/kg.
    • EXAMPLE 25 In Vivo Activity
  • The mouse protection test is an industry standard for measuring the efficacy of a test compound in vivo [for examples of this model see J. J. Clement, et al., Antimicrobial Agents and Chemotherapy, 38 (5), 1071-1078, (1994)]. As exemplified below, this test is used to demonstrate the in vivo efficacy of the compounds of the present invention against bacteria.
  • The in vivo antibacterial activity is established by infecting female CD-1 mice (Charles River Lab, MA) weighing 19-23 g intraperitoneally with Methicillin Resistant S. aureus (MRSA) inoculum. The inoculum is prepared from Methicillin Resistant S. aureus (ATCC 43300). The MRSA inoculum is cultured in Mueller-Hinton (MH) broth at 37° C. for 18 hours. The optical density at 600 nm (OD600) is determined for a 1:10 dilution of the overnight culture. Bacteria (8×108 cfu) is added to 20 ml of phosphate buffered saline (Sigma P-0261) containing 5% hog gastric mucin (Sigma M-2378). All animals are injected with 0.5 ml of the inoculum, equivalent to 2×107 cfu/mouse, which is the dose causing ˜100% death of the animals without treatment.
  • The test compound is dissolved in 10.0 ml of 50 mM phosphate buffer to give a solution of 1 mg/ml (pH=7.0). This solution is serially diluted with vehicle by 4-fold (1.5 ml to 6.0 ml) to give 0.25, 0.063 and 0.016 mg/ml solutions. All the solutions are filtered with 0.2 m Nalgene syringe filter. Immediately after the bacterial inoculation, group 1 animals are subcutaneously (sc) injected with buffer (no test compound) and groups 2 to 5 were given test compound sc at 10.0, 2.5, 0.63, and 0.16 mg/kg, respectively. Group 6 animals receive test compound sc at 10 mg/kg (or the highest therapeutic dose of a given compound) only for monitoring acute toxicity. These injections are repeated once at 4 hours after the inoculation for the respective groups. The injection volume at each time is 10 ml per kilogram of body weight. The 50% protective dose (PD50) is calculated on the basis of the number of mice surviving 7 days after inoculation.
  • All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims (25)

1. A pharmaceutical composition comprising a compound of the Formula:
Figure US20060194714A1-20060831-C00227
or a salt thereof; wherein:
(a) R is 2-butyl or isopropyl;
(b) each of R1 and R2 is independently methyl;
(c) R3 is —CH2CH2CH2CH2R9;
(d) R4 is methoxy;
(e) R5 is carboxyamino;
(f) R6 is hydrido or methyl;
(g) each of R7 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(h) provided that R7 is other than
Figure US20060194714A1-20060831-C00228
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl.
2. The composition of claim 1 wherein R7 is
Figure US20060194714A1-20060831-C00229
wherein each of Raa, Raa2 and Raa3 is independently an amino acid side chain and wherein R13 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
3. A composition comprising a compound of the Formula
Figure US20060194714A1-20060831-C00230
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R4 is hydrido or methoxy;
(d) R5 hydroxyl or carboxyamino;
(e) R15 is hydrido,
Figure US20060194714A1-20060831-C00231
wherein: R18 is amino or hydroxyl; R19 is hydrido or hydroxyl; and R20 is carboxyamino or carboxymethyl;
(f) R16 is methyl or —CH2CH2CH2R21;
(g) R17 is methyl or —CH2CH2CH2CH2R22;
wherein each of R21 and R22 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
4. The composition of claim 3 wherein each of R21 and R22 is independently —NHR23, wherein R23 is an amino protecting group.
5. The composition of claim 4 wherein the compound of Formula I is
Figure US20060194714A1-20060831-C00232
Figure US20060194714A1-20060831-C00233
Figure US20060194714A1-20060831-C00234
wherein each of R6 and R14 is independently hydrido or methyl.
6. A method of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically-effective amount of a composition comprising a compound of the Formula:
Figure US20060194714A1-20060831-C00235
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R2 is methyl or —CH2CH2CH2R8;
(d) R3 is methyl or —CH2CH2CH2CH2R9;
(e) R4 is hydrido or methoxy;
(f) R5 is hydroxyl or carboxyamino;
(g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(h) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00236
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00237
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl.
7. A process for preparing a compound of Formula I:
Figure US20060194714A1-20060831-C00238
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R2 is methyl or —CH2CH2CH2R8;
(d) R3 is methyl or —CH2CH2CH2CH2R9;
(e) R4 is hydrido or methoxy;
(f) R5 is hydroxyl or carboxyamino;
(g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(h) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00239
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00240
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl;
comprising removing an amino protecting group from a compound of Formula XVII,
Figure US20060194714A1-20060831-C00241
or a salt thereof,
wherein R28 is methyl or —CH2CH2CH2NHP; R29 is methyl or —CH2CH2CH2CH2NHP; and P is an amino protecting group; provided that at least one of R28 or R29 is other than methyl.
8. The process of claim 7 further comprising treating a compound of the Formula XVI,
Figure US20060194714A1-20060831-C00242
or a salt thereof,
with a modifying agent to obtain the compound of Formula XVII, or a salt thereof.
9. The process of claim 8 further comprising removing the terminal amino acid residue from a compound of Formula XV,
Figure US20060194714A1-20060831-C00243
or a salt thereof,
wherein R18 is amino or hydroxy; R19 is hydrido or hydroxy;
to obtain the compound of Formula XVI, or a salt thereof.
10. The process of claim 9 further comprising removing the terminal amino acid residue from a compound of Formula XIV
Figure US20060194714A1-20060831-C00244
or a salt thereof,
wherein R20 is carboxyamino or carboxymethyl;
to obtain the compound of Formula XV, or a salt thereof.
11. The process of claim 10 further comprising removing the tryptophan amino acid residue from a compound of Formula XIII
Figure US20060194714A1-20060831-C00245
or a salt thereof,
to obtain the compound of Formula XIV, or a salt thereof.
12. The process of claim 11 further comprising deacylating a compound of Formula XII
Figure US20060194714A1-20060831-C00246
or a salt thereof;
wherein R25 is an alkyl group;
to obtain the compound of Formula XIII, or a salt thereof.
13. The process of claim 12 further comprising protecting the free amine group(s) of a compound of Formula XI
Figure US20060194714A1-20060831-C00247
or a salt thereof;
wherein R26 methyl or —CH2CH2CH2NH2; and R27 is methyl or —CH2CH2CH2CH2NH2;
to obtain the compound of Formula XII, or a salt thereof.
14. A process for preparing a compound of Formula I:
Figure US20060194714A1-20060831-C00248
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R2 is methyl or —CH2CH2CH2R8;
(d) R3 is methyl or —CH2CH2CH2CH2R9;
(e) R4 is hydrido or methoxy;
(f) R5 is hydroxyl or carboxyamino;
(g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(h) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00249
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00250
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl;
comprising treating a compound of Formula Ia
Figure US20060194714A1-20060831-C00251
or salt thereof,
wherein R2a is methyl or —CH2CH2CH2NH2; and R3a is methyl or —CH2CH2CH2CH2NH2; provided at least one of R2a and R3a is other than methyl; with a modifying agent.
15. A process for preparing a compound of Formula I:
Figure US20060194714A1-20060831-C00252
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R2 is methyl or —CH2CH2CH2R8;
(d) R3 is methyl or —CH2CH2CH2CH2R9;
(e) R4 is hydrido or methoxy;
(f) R5 is hydroxyl or carboxyamino;
(g) each of R7, R8 and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(h) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00253
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00254
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl;
comprising treating a compound of Formula XXVIII
Figure US20060194714A1-20060831-C00255
or a salt thereof;
wherein R37 is methyl or —CH2CH2CH2R8; and R38 is methyl or —CH2CH2CH2CH2R9; provided that at least one of R37 and R38 is other than methyl and further provided that each of R8 and R9 is other than amino;
with a modifying agent.
16. The process of claim 15 further comprising removing the terminal amino acid residue from a compound of Formula XXVII
Figure US20060194714A1-20060831-C00256
or a salt thereof;
wherein R18 is amino or hydroxyl; and R19 is hydrido or hydroxyl;
to obtain the compound of Formula XXVIII, or a salt thereof.
17. The process of claim 16 further comprising removing the terminal amino acid residue from a compound of Formula XXVI
Figure US20060194714A1-20060831-C00257
or a salt thereof;
wherein R20 is carboxyamino or carboxymethyl;
to obtain the compound of Formula XXVII, or a salt thereof.
18. The process of claim 17 further comprising removing the tryptophan amino acid residue from a compound of Formula XXV
Figure US20060194714A1-20060831-C00258
or a salt thereof,
to obtain the compound of Formula XXVI, or a salt thereof.
19. The process of claim 18 further comprising deacylating a compound of Formula XXIV
Figure US20060194714A1-20060831-C00259
or a salt thereof;
wherein R25 is an alkyl group;
to obtain the compound of Formula XXV, or a salt thereof.
20. The process of claim 19 further comprising treating the free amine group(s) of a compound of Formula XI,
Figure US20060194714A1-20060831-C00260
or a salt thereof;
wherein R26 methyl or —CH2CH2CH2NH2; and R27 is methyl or —CH2CH2CH2CH2NR2;
with a modifying agent to obtain the compound of Formula XXV, or a salt thereof.
21. A process for preparing a compound of the Formula XXXII
Figure US20060194714A1-20060831-C00261
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R4 is hydrido or methoxy;
(d) R5 is hydroxyl or carboxyamino;
(e) R18 is amino or hydroxyl;
(f) R19 is hydrido or hydroxyl;
(g) R20 is carboxyamino or carboxymethyl;
(h) R28 is methyl or —CH2CH2CH2NHP;
(i) R29 is methyl or CH2CH2CH2CH2NHP;
(j) P is an amino protecting group;
(k) R39 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(l) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00262
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00263
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl;
comprising treating a compound of Formula XIV
Figure US20060194714A1-20060831-C00264
or a salt thereof,
with a modifying agent.
22. A process for preparing a compound of the Formula XXXIV
Figure US20060194714A1-20060831-C00265
or a salt thereof; wherein:
(a) R is 2-butyl, isopropyl or 2-(2′-aminophenacyl);
(b) each of R1 and R6 is independently hydrido or methyl;
(c) R4 is hydrido or methoxy;
(d) R5 is hydroxyl or carboxyamino;
(e) R18 is amino or hydroxyl;
(f) R19 is hydrido or hydroxyl;
(g) R28 is methyl or —CH2CH2CH2NHP;
(h) R29 is methyl or —CH2CH2CH2CH2NHP;
(i) P is an amino protecting group;
(j) R39 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino;
(k) provided that
(1) when R2 is —CH2CH2CH2R8, R7 is other than
Figure US20060194714A1-20060831-C00266
wherein R10 is amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, iminoamino, or phosphonamino;
(2) when R2 is methyl, R7 is other than
Figure US20060194714A1-20060831-C00267
wherein each of R11 and R12 is hydrido, C6-C18 unsubstituted alkanoyl, C8-C18 unsubstituted alkenoyl, C8-C18 unsubstituted alkyl, or C8-C18 select substituted alkyl; or alternatively, R11 and R12 together are C8-C18 alkylidenyl;
comprising treating a compound of Formula XV
Figure US20060194714A1-20060831-C00268
or a salt thereof,
with a modifying agent.
23. The composition according to claim 1 wherein the compound is selected from:
Figure US20060194714A1-20060831-C00269
 R7 R9
Figure US20060194714A1-20060831-C00270
 NH2
Figure US20060194714A1-20060831-C00271
 NH2
Figure US20060194714A1-20060831-C00272
 NH2
Figure US20060194714A1-20060831-C00273
 NH2
Figure US20060194714A1-20060831-C00274
 NH2
Figure US20060194714A1-20060831-C00275
 NH2
Figure US20060194714A1-20060831-C00276
 NH2
Figure US20060194714A1-20060831-C00277
 NH2
Figure US20060194714A1-20060831-C00278
 NH2
Figure US20060194714A1-20060831-C00279
 NH2
Figure US20060194714A1-20060831-C00280
 NH2
Figure US20060194714A1-20060831-C00281
 NH2
Figure US20060194714A1-20060831-C00282
 NH2
Figure US20060194714A1-20060831-C00283
 NH2
Figure US20060194714A1-20060831-C00284
 NH2
Figure US20060194714A1-20060831-C00285
 NH2
Figure US20060194714A1-20060831-C00286
 NH2
Figure US20060194714A1-20060831-C00287
 NH2
Figure US20060194714A1-20060831-C00288
 NH2
Figure US20060194714A1-20060831-C00289
 NH2
Figure US20060194714A1-20060831-C00290
 NH2
Figure US20060194714A1-20060831-C00291
 NH2
Figure US20060194714A1-20060831-C00292
 NH2
Figure US20060194714A1-20060831-C00293
 NH2
Figure US20060194714A1-20060831-C00294
 NH2
Figure US20060194714A1-20060831-C00295
 NH2
Figure US20060194714A1-20060831-C00296
 NH2
Figure US20060194714A1-20060831-C00297
 NH2
Figure US20060194714A1-20060831-C00298
 NH2
Figure US20060194714A1-20060831-C00299
 NH2
Figure US20060194714A1-20060831-C00300
 NH2
Figure US20060194714A1-20060831-C00301
 NH2
Figure US20060194714A1-20060831-C00302
 NH2
Figure US20060194714A1-20060831-C00303
 NH2
Figure US20060194714A1-20060831-C00304
 NH2
Figure US20060194714A1-20060831-C00305
 NH2
Figure US20060194714A1-20060831-C00306
 NH2
Figure US20060194714A1-20060831-C00307
 NH2
Figure US20060194714A1-20060831-C00308
 NH2
Figure US20060194714A1-20060831-C00309
 NH2
Figure US20060194714A1-20060831-C00310
 NH2
Figure US20060194714A1-20060831-C00311
 NH2
Figure US20060194714A1-20060831-C00312
 NH2
Figure US20060194714A1-20060831-C00313
 NH2
a) wherein R14 is hydrido or methyl;
b) wherein R7** is an amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino and
c) each of Raa4, Raa5, and Raa6 is independently an amino acid side chain.
24. A composition comprising a compound of the Formula:
Figure US20060194714A1-20060831-C00314
;
wherein R6 is H or CH3 and each of R7* and R9 is independently amino, monosubstituted amino, disubstituted amino, acylamino, ureido, guanidino, carbamoyl, sulfonamino, thioacylamino, thioureido, iminoamino, or phosphonamino.
25. A compound of the Formula 33:
Figure US20060194714A1-20060831-C00315
US11/414,762 2001-08-06 2006-04-28 Novel depsipeptides and process for preparing same Abandoned US20060194714A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/414,762 US20060194714A1 (en) 2001-08-06 2006-04-28 Novel depsipeptides and process for preparing same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31031301P 2001-08-06 2001-08-06
US10/213,389 US20030083240A1 (en) 2001-08-06 2002-08-06 Novel depsipeptides and process for preparing same
US11/414,762 US20060194714A1 (en) 2001-08-06 2006-04-28 Novel depsipeptides and process for preparing same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/213,389 Division US20030083240A1 (en) 2001-08-06 2002-08-06 Novel depsipeptides and process for preparing same

Publications (1)

Publication Number Publication Date
US20060194714A1 true US20060194714A1 (en) 2006-08-31

Family

ID=23201948

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/213,218 Expired - Fee Related US7262268B2 (en) 2001-08-06 2002-08-06 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
US10/213,389 Abandoned US20030083240A1 (en) 2001-08-06 2002-08-06 Novel depsipeptides and process for preparing same
US11/414,762 Abandoned US20060194714A1 (en) 2001-08-06 2006-04-28 Novel depsipeptides and process for preparing same
US11/448,066 Expired - Fee Related US7335726B2 (en) 2001-08-06 2006-06-06 Lipopeptide stereoisomers, methods for preparing same and useful intermediates
US12/022,470 Abandoned US20080119395A1 (en) 2001-08-06 2008-01-30 Novel Depsipeptides and Process for Preparing Same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/213,218 Expired - Fee Related US7262268B2 (en) 2001-08-06 2002-08-06 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
US10/213,389 Abandoned US20030083240A1 (en) 2001-08-06 2002-08-06 Novel depsipeptides and process for preparing same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/448,066 Expired - Fee Related US7335726B2 (en) 2001-08-06 2006-06-06 Lipopeptide stereoisomers, methods for preparing same and useful intermediates
US12/022,470 Abandoned US20080119395A1 (en) 2001-08-06 2008-01-30 Novel Depsipeptides and Process for Preparing Same

Country Status (15)

Country Link
US (5) US7262268B2 (en)
EP (2) EP1423137B1 (en)
JP (1) JP2005531486A (en)
KR (1) KR20040022233A (en)
CN (1) CN100352836C (en)
AT (1) ATE430160T1 (en)
AU (1) AU2002353775A1 (en)
BR (1) BR0211761A (en)
CA (2) CA2456761A1 (en)
DE (1) DE60232158D1 (en)
IL (1) IL160171A0 (en)
NZ (1) NZ531493A (en)
RU (1) RU2348647C2 (en)
WO (2) WO2003014147A1 (en)
ZA (1) ZA200400928B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643438B2 (en) 2018-07-20 2023-05-09 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2348647C2 (en) * 2001-08-06 2009-03-10 Кьюбист Фармасьютикалз, Инк New depsipeptides and methods of their obtainment
US6767718B2 (en) * 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
AU2004246909B2 (en) * 2003-06-19 2010-08-19 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2587848A1 (en) * 2004-11-12 2006-10-19 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US8968781B2 (en) * 2005-04-29 2015-03-03 Cubist Pharmaceuticals, Inc. Therapeutic compositions
WO2009132051A1 (en) * 2008-04-21 2009-10-29 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
RS53152B (en) * 2008-12-22 2014-06-30 Cubist Pharmaceuticals Inc. Novel antibacterial agents for the treatment of gram positive infections
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101899094B (en) * 2009-06-01 2012-11-21 安徽丰原发酵技术工程研究有限公司 Preparation method of high-purity Daptomycin
KR101013755B1 (en) * 2010-02-02 2011-02-14 주식회사 삼광산전 Converter for constant output power supply for led module
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN102351775B (en) * 2011-09-14 2013-10-09 佛山普正医药科技有限公司 Preparation method of levo-5-hydroxytryptophan
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
JP6634197B2 (en) * 2013-05-08 2020-01-22 株式会社ゲノム創薬研究所 Method for producing cyclic peptide compound using solid-phase resin
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
KR101671325B1 (en) * 2015-01-09 2016-11-02 한국생명공학연구원 Novel cyclic depsipeptide-based compound, separation method thereof, and antibacterial pharmaceutical composition containing the same as an active ingredient
US11667674B2 (en) * 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911525B2 (en) * 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) * 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) * 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) * 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) * 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) * 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) * 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5039789A (en) * 1988-04-11 1991-08-13 Eli Lilly And Company A54145 cyclic peptides
US4994270A (en) * 1988-04-11 1991-02-19 Eli Lilly And Company A54145 antibiotics and process for their production
US5028590A (en) * 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
US4977083A (en) * 1988-04-11 1990-12-11 Eli Lilly And Company Processes for preparing A54145 compounds
EP0460882B1 (en) * 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
JPH07507995A (en) * 1992-03-02 1995-09-07 バイオジェン，インコーポレイテッド thrombin receptor antagonist
DE4411025A1 (en) 1994-03-30 1995-10-05 Hoechst Ag New lipopeptide A1437 derivs. with modified acyl gp.
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
EP1854877B1 (en) 1996-03-08 2012-02-08 Astellas Pharma Inc. Process for the deacylation of cyclic lipopeptides
US5958728A (en) * 1996-11-18 1999-09-28 Novo Nordiskbiotech, Inc. Methods for producing polypeptides in mutants of bacillus cells
US20010041346A1 (en) 1999-07-14 2001-11-15 Michael E. Mendelsohn Method for assaying compounds affecting smooth muscle contractile state
WO2001044274A1 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
AU784942B2 (en) * 1999-12-15 2006-08-03 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6750199B2 (en) * 2000-07-17 2004-06-15 Micrologix Biotech Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
RU2348647C2 (en) * 2001-08-06 2009-03-10 Кьюбист Фармасьютикалз, Инк New depsipeptides and methods of their obtainment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911525B2 (en) * 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643438B2 (en) 2018-07-20 2023-05-09 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use

Also Published As

Publication number Publication date
EP1423137B1 (en) 2009-04-29
DE60232158D1 (en) 2009-06-10
US7262268B2 (en) 2007-08-28
WO2003017924A3 (en) 2004-03-04
IL160171A0 (en) 2004-07-25
WO2003014147A1 (en) 2003-02-20
WO2003017924A2 (en) 2003-03-06
AU2002353775A1 (en) 2003-03-10
CN100352836C (en) 2007-12-05
US20080119395A1 (en) 2008-05-22
US7335726B2 (en) 2008-02-26
ATE430160T1 (en) 2009-05-15
NZ531493A (en) 2006-03-31
CN1551887A (en) 2004-12-01
ZA200400928B (en) 2005-05-04
KR20040022233A (en) 2004-03-11
JP2005531486A (en) 2005-10-20
EP1423137A4 (en) 2005-11-30
CA2456323A1 (en) 2003-03-06
EP1423414A4 (en) 2005-11-30
EP1423137A2 (en) 2004-06-02
US20060223983A1 (en) 2006-10-05
US20030083240A1 (en) 2003-05-01
EP1423414A1 (en) 2004-06-02
CA2456761A1 (en) 2003-02-20
BR0211761A (en) 2007-01-09
RU2004106630A (en) 2005-06-27
RU2348647C2 (en) 2009-03-10
US20030096948A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
US20060194714A1 (en) Novel depsipeptides and process for preparing same
AU784942B2 (en) Daptomycin analogs and their use as antibacterial agents
AU784755B2 (en) Daptomycin Analogs as antibacterial agents
US20040067878A1 (en) Novel lipopeptides as antibacterial agents
EP1932853A1 (en) Novel depsipeptides and process for preparing same
AU2002326534A1 (en) Novel depsipeptides and process for preparing same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION